CA3019333C - Quinazoline derivative or its salt and pharmaceutical composition comprising the same - Google Patents

Quinazoline derivative or its salt and pharmaceutical composition comprising the same Download PDF

Info

Publication number
CA3019333C
CA3019333C CA3019333A CA3019333A CA3019333C CA 3019333 C CA3019333 C CA 3019333C CA 3019333 A CA3019333 A CA 3019333A CA 3019333 A CA3019333 A CA 3019333A CA 3019333 C CA3019333 C CA 3019333C
Authority
CA
Canada
Prior art keywords
amino
quinazoline
group
oxo
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3019333A
Other languages
French (fr)
Other versions
CA3019333A1 (en
Inventor
Young-Hwan Kim
Tae-Dong Han
Dong-Hoon Kim
Eun-Hye Jung
Su-Bin CHOI
Eui-Chul LEE
Won-Ee CHONG
Jin-Hwi PARK
Jun-Chul Park
Ho-Woong Kang
Ji-Yeong GAL
Chan-Sun Park
Jong-Gyun Kim
Su-Youn NAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of CA3019333A1 publication Critical patent/CA3019333A1/en
Application granted granted Critical
Publication of CA3019333C publication Critical patent/CA3019333C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides a quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The quinazoline derivative or its pharmaceutically acceptable salt has a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.

Description

Description Title of Invention: QUINAZOLINE DERIVATIVE OR ITS SALT
AND PHARMACEUTICAL COMPOSITION COMPRISING THE
SAME
Technical Field [11 The present invention relates to a quinazoline derivative or its pharmaceutically ac-ceptable salt having a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, a process for the preparation thereof, a pharmaceutical com-position comprising the same and a use thereof.
Background Art
[2] Phosphatidylinositol 3-kinase (PI3K), a lipid kinase which phosphorylates the lipid at the 3-hydroxy residue of the inositol ring, is known to play a critical role in pro-liferation, survival, motility and so on of cells. Class I PI3Ks (PI3Ka, P131(13, PI31(8, and PI3Ky) are activated by receptor tyrosine kinases or GPCR (G-protein coupled receptor) to produce PIP3 (phosphatidylinositol 3,4,5-triphosphate), thereby activating the Akt. It has been known that the activated Akt phosphorylates TSC2, GSK313, MDM2, FOXO, BAD and so on, thereby controlling cellular proliferation or survival, angiogenesis, etc. (Nature Rev. Cancer, 5, 921-929 (2005)).
[3] Class I PI3Ks are a heterodimer consisting of a p110 catalytic subunit and a regulatory subunit, and the family is further divided into Class IA and Class TB
enzymes on the basis of the regulatory partners and the regulatory mechanisms.
Class IA enzymes consist of three catalytic subunits (p1 10a, p11013 and p1108), which dimerize with five regulatory subunits (p85a, p55a, p50a, p8513 and p55y), where all catalytic subunits are able to interact with all regulatory subunits to fain' various het-erodimers. Class IA PI3Ks are generally activated in response to growth factor stimulation of receptor tyrosine kinases via interaction of the regulatory subunit SH2 domain with specific phospho-tyrosine residues of the activated receptor or adapter proteins, such as IRS-1. Both p110a and p11013 are expressed in all cell types, whereas p1108 expression is more restricted to inflammatory cells including leukocytes and some epithelial cells. The only class IB enzyme consists of a p120y catalytic subunit (also commonly referred to as p1 by), which interacts with a p101 regulatory subunit (Cell, Vol. 89, 105-114 (1997)). In addition, it has been reported that the Class IB
enzyme is activated by G-protein-coupled receptor systems (GPCRs) and expressed mainly in inflammatory cells, including leukocytes and macrophages, and car-diomyocytes (Curr. Opin. Pharmacol. 3(4), 426-434 (2003); Thromb Haemost 99:
279-285 (2008)).
[4] The PI3K/AKT/mTOR pathway is important for the formation and development of cancer, and mutations in the PIK3CA gene expressing p1 10a, along with PTEN, are frequently observed in cancer. Accordingly, PI3Ka and PI3KI3 inhibitors or non-specific class I inhibitors have been developed as a therapeutic agent for carcinomas overexpressing a specific subunit of PI3Ks. Although said inhibitors initially appeared to show some efficacy, it has been revealed to have limited therapeutic effects due to dose-related side effects and resistant mechanisms that activate alternative signals.
[5] PI3K inhibitors can attack cancer as an anticancer agent, through activating the anti-tumor immune responses. This has been suggested by studies in which the function of the PI3K8 subunit was genetically inhibited through transgenic mice or in which a PI3K8 subunit-specific inhibitor was administered to mice (Nature 2014, 510:
407-411). Suppression of the PI3K6 subunit function in the mouse models of lung cancer, breast cancer and pancreatic cancer inhibited the function of regulatory T cells (Tregs) as well as the migration of Tregs to tumors. It has been demonstrated that sup-pression of the PI3K6 subunit in animal models inhibits the regulatory T
cells, thereby resulting in an anti-tumor immune environment that can inhibit cancer proliferation by host immunity. Therefore, it has been established that the method for specifically in-hibiting the PI3K8 subunit can be a mechanism of an immunological anticancer agent which induces immunity against cancer.
[6] In order to identify the role of PI3K8 and PI3Ky, which are important subunits in the function of immune cells, studies have been conducted on mouse models lacking both genes (Blood, 2007, 110:2940-2947). According to the study, knock-out mice lacking both subunits display severe impairment of thymocyte development in the thymus, which leads to lymphopenia-associated inflammatory responses. And also, the other study has also reported that mice deficient in both PI3K6 and PI3Ky subunits have a profound block in T cell development (J. immunol., 2005, 175:2783-2787).
Therefore, considering that normal T cell differentiation is important for inflammatory response as well as for anti-cancer immunity, it is expected that selective inhibition against only the PI3K8 subunit (i.e., not inhibition against both PI3K8 and PI3Ky subunits) is a safer approach in terms of immune side effects.
Disclosure of Invention Technical Problem
[7] The present inventors has found that a certain quinazoline derivative or its pharma-ceutically acceptable salt has a selective inhibitory activity against the PI3K8 subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.
[8] Therefore, the present invention provides the above quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharma-ceutical composition comprising the same, and a use thereof.
Solution to Problem [91 According to an aspect of the present invention, there is provided a quinazoline-containing fused ring compound and its pharmaceutically acceptable salt.
[10] According to another aspect of the present invention, there is provided a process for preparing said quinazoline-containing fused ring compound and its pharmaceutically acceptable salt.
[11] According to still another aspect of the present invention, there is provided a pharma-ceutical composition comprising said quinazoline-containing fused ring compound or its pharmaceutically acceptable salt as an active ingredient.
[12] According to still another aspect of the present invention, there is provided a therapeutic method comprising administering said quinazoline-containing fused ring compound or its pharmaceutically acceptable salt.
[13] According to still another aspect of the present invention, there is provided a use of said quinazoline-containing fused ring compound or its pharmaceutically acceptable salt for the manufacture of a medicament for preventing or treating cancer.
Advantageous Effects of Invention [14] The compound of the present invention, i.e., the quinazoline-containing fused ring compound or its pharmaceutically acceptable salt has a selective inhibitory activity against the PI310 subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated in-flammatory responses. And also, co-administration of the compound or its pharma-ceutically acceptable salt of the present invention with an immune-checkpoint inhibitor, e.g., a negative regulating antibody of T-lymphocyte activation (for example, anti-PDL1 antibodies) can exhibit synergistic anticancer activity.
Brief Description of Drawings [15] FIG. 1 shows the results obtained by evaluating the anti-tumor efficacies of the compound according to the present invention and/or the immune-checkpoint inhibitor in murine syngeneic tumor model.
Best Mode for Carrying out the Invention [16] As used herein, the term "alkyl" refers to a straight or branched aliphatic hy-drocarbon radical. For example, the C1_6 alkyl means a straight or branched aliphatic hydrocarbon having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, n-butyl, n -pentyl, n-hexyL isopropyl, isobutyl, sec-butyl, tert-butyl, neopentyl, and isopentyl.
[17] The term "hydroxy" refers to the '-OH' group. The term "alkoxy" refers to a radical formed by substituting the hydrogen atom in the hydroxyl group with an alkyl.
For example, the C1-C6 alkoxy group includes methoxy, ethoxy, propoxy, n-butoxy, n -pentyloxy, isopropoxy, sec-butoxy, tert-butoxy, neopentyloxy, and isopentyloxy.
[18] The term "halogen" refers to the fluoro, bromo, chloro, or iodo group.
[19] The term "amino" refers to the '-NH2' group. The term "alkylamino"
refers to an amino group substituted with mono- or di-alkyl. For example, the C1.6 alkylamino group includes an amino group substituted with mono- or di-C16 alkyl group.
[20] The term "alkylthio" refers to the '-SR' group, in which R is an alkyl. The term "cyano" refers to the '-CN'.
[21] The present invention provides a compound or its pharmaceutically acceptable salt having a selective inhibitory activity against the P131(8 subunit, i.e., a compound of Formula 1 or its pharmaceutically acceptable salt:
[22] <Formula 1>
[23] R1 N"--LN

N
VIIII) W
HN.., Cy [24] wherein, [25] W is N or CH, [26] R1 is hydrogen; a C16 alkyl group; a C38 cycloalkyl group; a C16 alkoxy group; an amino group; a C16 alkylamino group; a C16 akylthio group; or a halogen group, [27] R2 is hydrogen; a C16 alkyl group; a C3 8 cycloalkyl group; a C38 heterocycloalkyl group; a substituted or unsubstituted aryl group; or a substituted or unsubstituted heteroaryl group, [28] R3 is hydrogen; a C16 alkyl group; a C38 cycloalkyl group; or a C38 heterocycloalkyl group, and [29] Cy is a goup of the following Formula A or B, where * in Formulas A
and B
represents the position attached to the compound of Formula 1 [30]
*
nor N N
A
[31] As used herein, the expression "having a selective inhibitory activity against the P131(8 subunit" refers to 'having significantly higher inhibitory activity against the PI3K8 subunit, among the PI3Ka, PI3K13, PI3K8, and PI3Ky subunits'. In an em-bodiment, the expression "significantly higher inhibitory activity against the PI3Ko subunit" means that the IC50 against the P131(8 subunit obtained from an in vitro enzyme assay is at least 3 times lower than the IC50 against the PI3Ky subunit obtained therefrom. In another embodiment, the expression "significantly higher inhibitory activity against the PI3K8 subunit" means that the IC50 against the P1310 subunit obtained from an in vitro enzyme assay is at least 25 times lower than the IC50 against the PI3Ka subunit obtained therefrom, at least 200 times lower than the IC50 against the PI31(13 subunit obtained therefrom, and at least 3 times lower than the IC50 against the PI3Ky subunit obtained therefrom.
[32] In the compound of Formula 1 or its pharmaceutically acceptable salt, R2 may be a C
3-8 cycloalkyl group or a phenyl group optionally substituted with halogen.
[33] And also, in the compound of Formula 1 or its pharmaceutically acceptable salt, R3 may be a C1_6 alkyl group or a C3_8 cycloalkyl group.
[34] In an embodiment of the present invention, there is provided a compound of Formula la or its pharmaceutically acceptable salt wherein W is N:
[35] <Formula la>
[36] R1 N N

Rs HN
Cy [37] wherein, RI, R2, R3 and Cy are the same as defined in the above.
[38] In the compound of Formula la or its pharmaceutically acceptable salt, RI may be hydrogen; a C16 alkyl group; a C16 alkoxy group; an amino group; a C16 alkylamino group; a C1_6 alkylthio group; or a halogen group. Preferably, R1 may be hydrogen; a C
16 alkyl group; a C1_6 alkoxy group; an amino group; a C,.6 alkylthio group;
or a halogen group. More preferably, RI may be hydrogen; a C,6 alkyl group; a C,6 alkoxy group; or an amino group. Particularly preferably, R1 may be C,6 alkoxy group or an amino group. In the compound of Formula la or its pharmaceutically acceptable salt, R
2 may be a C3 g cycloalkyl group or a phenyl group. Preferably, R2 may be a phenyl group. In the compound of Formula la or its pharmaceutically acceptable salt, R3 may be a C16 alkyl group or a C3, cycloalkyl group.
[39] In an embodiment of the compound of Formula la or its pharmaceutically acceptable salt, RI is hydrogen; a C1_6 alkyl group; a C,.6 alkoxy group; an amino group;
a C,.6 alkylamino group; a C16 alkylthio group; or a halogen group, R2 is a C3 cycloalkyl group or a phenyl group, and R3 is a C16 alkyl group or a C3,, cycloalkyl group. In another embodiment of the compound of Formula la or its pharmaceutically ac-ceptable salt, RI is hydrogen; a C1_6 alkyl group; a C1_6 alkoxy group; an amino group; a C16 alkylthio group; or a halogen group, R2 is a C3, cycloalkyl group or a phenyl group, and R3 is a C,6 alkyl group or a C38 cycloalkyl group. In still another em-bodiment of the compound of Formula la or its pharmaceutically acceptable salt, R1 is hydrogen; a C1_6 alkyl group; a Cl_6 alkoxy group; or an amino group, R, is a C3_8 cy-cloalkyl group or a phenyl group, and R3 is a C16 alkyl group or a C3,, cycloalkyl group. In a preferable embodiment of the compound of Formula la or its pharma-ceutically acceptable salt, R1 is a C1_6 alkoxy group or an amino group, R2 is a phenyl group, and R3 is a C1_6 alkyl group or a C3_8 cycloalkyl group.
[40] In the compound of Formula la or its pharmaceutically acceptable salt, preferable compounds include a compound or its pharmaceutically acceptable salt selected from the group consisting of:
[41] (S)-4-((1-(4-oxo-3-pheny1-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-ypethyeamin o)quinazoline-6-carbonitrile;
[42] (S)-4-41-(5-(2-aminopyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-ypeth yl)amino)quinazoline-6-carbonitrile;
[43] (S)-44(1-(5-(2-methylpyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-ypet hyl)amino)quinazoline-6-carbonitrile;
[44] (S)-4-41-(4-oxo-3-pheny1-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yppropyl)ami no)quinazoline-6-carbonitrile;
[45] (S)-4-01-(5-(2-methoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-y1) propyl)amino)quinazoline-6-carbonitrile;

[46] (S)-4-((1-(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)pr opyl)amino)quinazoline-6-carbonitrile;
[47] (S)-4-((1-(5-(2-(dimethylamino)pyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazol in-2-yl)propyl)amino)quinazoline-6-carbonitrile;
[48] (S)-44(1-(5-(2-(methylsulfanyl)pyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazol in-2-yl)propyl)amino)quinazoline-6-carbonitrile;
[49] (S)-4-((1-(5-(2-methylpyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)b utyl)amino)quinazoline-6-carbonitrile;
[50] (S)-4-((1-(5-(2-methoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-y1) butyl)amino)quinazoline-6-carbonitrile;
[51] (S)-4-((1-(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)bu tyl)amino)quinazoline-6-carbonitrile;
[52] (S)-4-((1-(5-(2-aminopyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)bu tyl)amino)quinazoline-6-carbonitrile;
[53] (S)-4-((1-(5-(2-aminopyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-y1)-2-methylpropyl)amino)quinazoline-6-carbonitrile;
[54] (S)-4-((cyclopropy1(4-oxo-3-pheny1-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-y1) methypamino)quinazoline-6-carbonitrde;
[55] (S)-4-((cyclopropy1(5-(2-methoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinaz olin-2-yl)methyeamino)quinazoline-6-carbonitrile;
[56] (S)-4-((cyclopropy1(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-phenyl-3,4-dihydroquinazol in-2-yl)methyl)amino)quinazoline-6-carbonitrile;
[57] (S)-4-41-(3-cyclopropy1-4-oxo-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-ypethyl) amino)quinazoline-6-carbonitrile;
[58] (S)-4-((1-(3-cyclopropy1-5-(2-methoxypyrimidin-5-y1)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile;
[59] (S)-4-41-(3-cyclopropy1-5-(2-ethoxypyrimidin-5-y1)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile;
[60] (S)-4-((1-(3-cyclopropy1-4-oxo-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yl)propy 1)amino)quinazoline-6-carbonitrile;
[61] (S)-4-((1-(5-(2-aminopyrimidin-5-y1)-3-cyclopropy1-4-oxo-3,4-dihydroquinazolin-2-yl)propyl)amino)quinazoline-6-carbonitrile;
[62] (S)-2-(1-((5-fluoroquinazolin-4-yl)amino)ethyl)-3-phenyl-5-(pyrimidin-5-y1)quinazol in-4(3H)-one;
[63] (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yl)amino)ethyl)-3-phenyl quinazolin-4(3H)-one;
[64] (S)-2-(1-((5-fluoroquinazolin-4-yeamino)propy1)-3-pheny1-5-(pyrimidin-5-yDquinaz olin-4(3H)-one;

[65] (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yl)amino)propy1)-3-phen ylquinazolin-4(3H)-one;
[66] (S)-5-(2-fluoropyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yl)amino)propy1)-3-phen ylquinazolin-4(3H)-one;
[67] (S)-2-(1-((5-fluoroquinazolin-4-yl)amino)propy1)-5-(2-methylpyrimidin-5-y1)-3-phen ylquinazolin-4(3H)-one;
[68] (S)-2-(1-((5-fluoroquinazolin-4-yl)amino)-2-methylpropy1)-3-phenyl-5-(pyrimidin-5-yl)quinazolin-4(3H)-one;
[69] (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yl)amino)-2-methylpropy 1)-3-phenylquinazolin-4(3H)-one;
[70] (S)-2-(cyclopropyl((5-fluoroquinazolin-4-yDamino)methyl)-3-phenyl-5-(pyrimidin-5 -yl)quinazolin-4(31/)-one; and [71] (S)-5-(2-aminopyrimidin-5-y1)-2-(cyclopropyl((5-fluoroquinazolin-4-yeamino)meth y1)-3-phenylquinazolin-4(3H)-one.
[72] In the compound of Formula la or its pharmaceutically acceptable salt, more preferable compounds include a compound or its pharmaceutically acceptable salt selected from the group consisting of:
[73] (S)-4-((1-(4-oxo-3-pheny1-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yl)ethyl)amin o)quinazoline-6-carbonitrile;
[74] (S)-4-((1-(5-(2-methylpyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-ypet hyl)amino)quinazoline-6-carbonitrile;
[75] (S)-4-((1-(4-oxo-3-pheny1-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yl)propyl)ami no)quinazoline-6-carbonitrile;
[76] (S)-4-((1-(5-(2-methoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-y1) propyl)amino)quinazoline-6-carbonitrile;
[77] (S)-4-((1-(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)pr opyl)amino)quinazoline-6-carbonitrile;
[78] (S)-4-((1-(5-(2-(methylsulfanyl)pyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazol in-2-yl)propyl)amino)quinazoline-6-carbonitrile;
[79] (S)-4-((1-(5-(2-methylpyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)b utyl)amino)quinazoline-6-carbonitrile;
[80] (S)-4-((1-(5-(2-aminopyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-y1)-2-methylpropyl)amino)quinazoline-6-carbonitrile;
[81] (S)-4-((cyclopropy1(4-oxo-3-pheny1-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-y1) methypamino)quinazoline-6-carbonitrile;
[82] (S)-4-((cyclopropy1(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazol in-2-yOmethyeamino)quinazoline-6-carbonitrile;
[83] (S)-4-((1-(3-cyclopropy1-4-oxo-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yl)ethyl) amino)quinazoline-6-carbonitrile;
[84] (S)-4-((1-(3-cyclopropy1-5-(2-methoxypyrimidin-5-y1)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile;
[85] (S)-44(1-(3-cyclopropy1-5-(2-ethoxypyrimidin-5-y1)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile;
[86] (S)-4-((1-(3-cyclopropy1-4-oxo-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yl)propy Damino)quinazoline-6-carbonitrile;
[87] (S)-2-(1-((5-fluoroquinazolin-4-yl)amino)ethyl)-3-phenyl-5-(pyrimidin-5-y1)quinazol in-4(3H)-one;
[88] (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yl)amino)ethyl)-3-phenyl quinazolin-4(3H)-one;
[89] (S)-2-(1-((5-fluoroquinazolin-4-yl)amino)propy1)-3-phenyl-5-(pyrimidin-5-ypquinaz olin-4(3H)-one;
[90] (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yl)amino)propy1)-3-phen ylquinazolin-4(3H)-one;
[91] (S)-5-(2-fluoropyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yl)amino)propy1)-3-phen ylquinazolin-4(3H)-one;
[92] (S)-2-(1-((5-fluoroquinazolin-4-yl)amino)propy1)-5-(2-methylpyrimidin-5-y1)-3-phen ylquinazolin-4(3H)-one;
[93] (S)-2-(1-((5-fluoroquinazolin-4-yl)amino)-2-methylpropy1)-3-phenyl-5-(pyrimidin-5-y1)quinazolin-4(3H)-one;
[94] (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yl)amino)-2-methylpropy 1)-3-phenylquinazolin-4(3H)-one; and [95] (S)-2-(cyclopropyli(5-fluoroquinazolin-4-yDamino)methyl)-3-phenyl-5-(pyrimidin-5 -yl)quinazolin-4(3H)-one.
[96] In the compound of Formula la or its pharmaceutically acceptable salt, still more preferable compounds include a compound or its pharmaceutically acceptable salt selected from the group consisting of:
[97] (S)-4-((1-(5-(2-methylpyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)et hyl)amino)quinazoline-6-carbonitrile;
[98] (S)-4-41-(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yppr opyl)amino)quinazoline-6-carbonitrile;
[99] (S)-4-((cyclopropy1(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-phenyl-3,4-dihydroquinazol in-2-yl)methyl)amino)quinazoline-6-carbonitrile;
[100] (S)-4-41-(3-cyclopropy1-4-oxo-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yl)ethyl) amino)quinazoline-6-carbonitrile;
[101] (S)-4-((1-(3-cyclopropy1-5-(2-methoxypyrimidin-5-y1)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile;

[102] (S)-4-((1-(3-cyclopropy1-5-(2-ethoxypyrimidin-5-y1)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile;
[103] (S)-2-( 14(5 -fluoroquinazolin-4- yl)amino)ethyl)-3-pheny1-5 -(p yrimidin-5 -yl)q uinazol in-4(3H)-one;
[104] (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yeamino)ethyl)-3-phenyl quinazolin-4(3H)-one;
[105] (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yl)amino)propy1)-3-phen ylquinazolin-4(3H)-one;
[106] (S)-2-(1-((5-fluoroquinazolin-4-yl)amino)propy1)-5-(2-methylpyrimidin-5-y1)-3-phen ylquinazolin-4(3H)-one; and [107] (S)-2-( 14(5 -fluoroquinazolin-4- yl)amino)-2-methylpropy1)-3-pheny1-5 -(pyrimidin-5-yl)quinazolin-4(3H)-one.
[108] In the compound of Formula la or its pharmaceutically acceptable salt, particularly preferable compounds include a compound or its pharmaceutically acceptable salt selected from the group consisting of:
[109] (S)-4-41-(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yppr opyl)amino)quinazoline-6-carbonitrile;
[110] (S)-4-((cyclopropy1(5 -(2-ethoxypyrimidin-5-y1)-4-oxo-3-phenyl-3 ,4-dihydroq uinazol in-2-yOmethyl)amino)quinazoline-6-carbonitrile;
[111] (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yeamino)ethyl)-3-phenyl quinazolin-4(3H)-one; and [112] (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin-4-yl)amino)propy1)-3-phen ylquinazolin-4(3H)-one.
[113] The compound of Formula la may be (S)-4-((1-(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)pro pyl)amino)quinazoline-6-carbonitrile or its pharmaceutically acceptable salt.
[114] The compound of Formula la may be (S)-4-((cyclopropy1(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-phenyl-3,4-dihydroquinazolin -2-yl)methyl)amino)quinazoline-6-carbonitrile or its pharmaceutically acceptable salt.
[115] The compound of Formula la may be (S)-5-(2-aminopyrimidin-5-y1)-2-(14(5-fluoroquinazolin-4-yl)amino)ethyl)-3-phenylq uinazolin-4(3H)-one or its pharmaceutically acceptable salt.
[116] The compound of Formula la may be (S)-5 -(2- aminop yrimidin-5- y1)-2-(1-((5-fluoroq uinazolin-4- yl)amino)prop y1)-3-phenyl quinazolin-4(3H)-one or its pharmaceutically acceptable salt.
[117]
[118] In another embodiment of the present invention, there is provided a compound of Formula lb or its pharmaceutically acceptable salt wherein W is CH:

[119] <Formula lb>
[120]

RHN
Cy [121] wherein, RI, R2, R3 and Cy are the same as defined in the above.
[122] In the compound of Formula lb or its pharmaceutically acceptable salt, R1 may be hydrogen; a C1_6 alkyl group; a C3_8 cycloalkyl group; a C1_6 alkoxy group; an amino group; a C16 alkylamino group; or a halogen group. Preferably, RI may be hydrogen; a C16 alkyl group; a C16 alkoxy group; an amino group; or a halogen group. More preferably, R1 may be a C1_6 alkyl group or a C1_6 alkoxy group. In the compound of Formula lb or its pharmaceutically acceptable salt, R2 may be a phenyl group op-tionally substituted with halogen. Preferably, R2 may be a phenyl group. In the compound of Formula lb or its pharmaceutically acceptable salt, R3 may be a C16 alkyl group.
[123] In an embodiment of the compound of Formula lb or its pharmaceutically acceptable salt, RI is hydrogen; a C16 alkyl group; a C38 cycloalkyl group; a C16 alkoxy group; an amino group; a C1, alkylamino group; or a halogen group, R2 is a phenyl group op-tionally substituted with halogen, and R3 is a C1_6 alkyl group. In another embodiment of the compound of Formula lb or its pharmaceutically acceptable salt, RI is hydrogen;
a C16 alkyl group; a C16 alkoxy group; an amino group; or a halogen group, R2 is a phenyl group, and R3 is a C16 alkyl group. In a preferable embodiment of the compound of Formula lb or its pharmaceutically acceptable salt, R1 is a C1_6 alkyl group or a C1_6 alkoxy group, R2 is a phenyl group, and R3 is a C1_6 alkyl group.
[124] In the compound of Formula lb or its pharmaceutically acceptable salt, preferable compounds include a compound or its pharmaceutically acceptable salt selected from the group consisting of:
[125] (S)-4-01-(1-oxo-2-phenyl-8-(pyrimidin-5-y1)-1,2-dihydroisoquinolin-3-ypethypami no)quinazoline-6-carbonitrile;
[126] (S)-4-41-(8-(2-rnethoxypyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-y1 )ethyl)amino)quinazoline-6-carbonitrile;

[127] (S)-44(1-(8-(2-ethoxypyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)et hyl)amino)quinazoline-6-carbonitrile;
[128] (S)-4-((1-(8-(2-(dimethylamino)pyrimidin-5- y1)- 1-oxo-2-phenyl- 1,2-dihydroi soq uino lin-3-ypethypamino)quinazoline-6-carbonitrile;
[129] (S)-4-((1-(8-(2-methylpyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)e thyl)amino)quinazoline-6-carbonitrile;
[130] (S)-4-((1-(8-(2-cyclopropylpyrimidin-5-y1)- 1-oxo-2-phenyl- 1,2-dihydroisoquinolin-3 -ypethypamino)quinazoline-6-carbonitrile;
[131] (S )-4-((1-(2-(4-fl uoropheny1)-8-(2-methy 1pyrimidin-5-y1)-1 -oxo- 1 ,2-dihy droi soquino lin-3-yl)ethyl)amino)quinazoline-6-carbonitrile;
[132] (S)-4-((1-(1-oxo-2-pheny1-8-(pyrimidin-5-y1)-1,2-dihydroisoquinolin-3-yl)propyl)am ino)quinazoline-6-carbonitrile;
[133] (S )-4-((1-(8-(2-methoxypyrimidin-5 -y1)-1-oxo-2-phenyl- 1,2-dihydroisoquinolin-3-y1 )propyl)amino)quinazoline-6-carbonitrile;
[134] (S)-4-01-(8-(2-ethoxypyrimidin-5 -y1)- 1-oxo-2-phenyl- 1,2-dihydroisoquinolin-3-yl)p ropyl)amino)quinazoline-6-carbonitrile;
[135] (S)-4-((1-(8-(2-methylpyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)p ropyl)amino)quinazoline-6-carbonitrile;
[136] (S)-8-(2-aminopyrimidin-5-y1)-3-(1-((5-fluoroquinazolin-4-yl)amino)ethyl)-2-phenyl isoquinolin-1(2H)-one;
[137] (S)-8-(2-fluoropyrimidin-5-y1)-3-(1-((5-fluoroquinazolin-4-yl)amino)ethyl)-2-phenyl isoquinolin-1(2H)-one;
[138] (S)-3-(1-((5-fluoroquinazolin-4- yl)amino)-2-methylpropy1)-2-phenyl-8-(pyrimidin-5-y 1)i soquinolin-1(2H)-one;
[139] (S)-8-(2-aminopyrimidin-5-y1)-3-(1-((5-fluoroquinazolin-4-yl)amino)-2-methylpropy 1)-2-phenylisoquinolin-1(2H)-one; and [140] (S)-3-(1-((5-fluoroquinazolin-4-yl)amino)-2-methylpropy1)-8-(2-methylpyrirnidin-5-y1)-2-phenylisoquinolin-1(2H)-one.
[141] In the compound of Formula lb or its pharmaceutically acceptable salt, more preferable compounds include a compound or its pharmaceutically acceptable salt selected from the group consisting of:
[142] (S)-4-((1-(8-(2-ethoxypyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)et hyl)amino)quinazoline-6-carbonitrile;
[143] (S)-4-((1-(8-(2-methy 1p yrimidin-5 - y1)- 1-oxo-2-phenyl-1,2-dihydroisoquinolin-3- yl)e thyl)amino)quinazoline-6-carbonitrile;
[144] (S)-4-((1-(8-(2-ethoxypyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)p ropy Damino)quinazoline-6-carbonitrile ;
[145] (S)-4-((1-(8-(2-methy 1p yrimidin-5 - y1)- 1-oxo-2-phenyl-1,2-dihydroisoquinolin-3- yl)p ropyl)amino)quinazoline-6-carbonitrile;
[146] (S)-8-(2-fluoropyrimidin-5-y1)-3-(1-((5-fluoroquinazolin-4-yl)amino)ethyl)-2-phenyl isoquinolin-1(2H)-one;
[147] (S)-3-(1-((5-fluoroquinazolin-4-yl)arnino)-2-methylpropy1)-2-phenyl-8-(pyrimidin-5-yl)isoquinolin-1(2H)-one;
[148] (S)-8-(2-aminopyrimidin-5-y1)-3-(1-((5-fluoroquinazolin-4-yl)amino)-2-methylpropy 1)-2-phenylisoquinolin-1(2H)-one; and [149] (S)-3-(1-((5-fluoroquinazolin-4-yl)arnino)-2-methylpropy1)-8-(2-methylpyrirnidin-5-y1)-2-phenylisoquinolin-1(2H)-one.
[150] In the compound of Formula lb or its pharmaceutically acceptable salt, particularly preferable compounds include a compound or its pharmaceutically acceptable salt selected from the group consisting of:
[151] (S)-4-41-(8-(2-ethoxypyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)et hyl)amino)quinazoline-6-carbonitrile;
[152] (S)-4-((1-(8-(2-methylpyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)e thyl)amino)quinazoline-6-carbonitrile; and [153] (S)-4-((1-(8-(2-methylpyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)p ropyl)amino)quinazoline-6-carbonitrile.
[154] The compound of Formula lb may be (S)-4-41-(8-(2-ethoxypyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)eth yl)amino)quinazoline-6-carbonitrile or its pharmaceutically acceptable salt.
[155] The compound of Formula lb may be (S)-4-((1-(8-(2-methylpyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-ypeth yl)amino)quinazoline-6-carbonitrile or its pharmaceutically acceptable salt.
[156] The compound of Formula lb may be (S)-4-((1-(8-(2-methylpyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)pro pyl)amino)quinazoline-6-carbonitrile or its pharmaceutically acceptable salt.
[157]
[158] The compound of Formula 1 or its pharmaceutically acceptable salt may have sub-stituents containing asymmetric carbon (for example, the substituent R3) and therefore be in the form of racemic mixture (RS) or in forms of optical isomers, such as (R) or (S) isomer. The compound of Formula 1 or its pharmaceutically acceptable salt comprises both racemic mixture (RS) and optical isomers such as (R) or (S) isomer.
[159] The compound of Formula 1 of the present invention may be in a pharmaceutically acceptable salt form. The salt may be a conventional acid addition salt form, which includes, but not limited thereto, e.g., salts derived from an inorganic acid such as hy-drochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid or carbonic acid; and salts derived from an organic acid such as citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, lactobionic acid, salicylic acid, malonic acid, fot __ Mc acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, glutamic acid, or aspartic acid. And also, the salt includes a conventional metal salt form, e.g., salts derived from an alkali metal such as lithium, sodium, or potassium; salts derived from an alkaline earth metal such as calcium or magnesium; or a chromium salt.
[160]
[161] The compound of Formula 1 or its pharmaceutically acceptable salt of the present invention may be prepared according to various methods. For example, the compound of Formula 1 or its pharmaceutically acceptable salt of the present invention may be prepared according to the following exemplary reaction schemes 1 to 3, but not limited thereto.
[162] <Reaction Scheme 1>
[163] 0 OH

NHBoc NH2 [164] In the above Reaction Scheme 1, X is halogen, Boc is an amino-protecting group (for example, tert-butoxycarbonyl), and R2 and R3 are the same as defined in the above.
[165] The compound of Formula 3 may be prepared by coupling the compound of Formula 2 with an amino acid (e.g., N-(tert-butoxycarbony1)-L-alanine, etc.) in the presence of triphenyl phosphite and pyridine at about 70 C and then dehydrogenating with an ap-propriate aniline derivative. The protecting group in the compound of Formula 3 may be removed through the reaction with an acid, such as hydrochloric acid or trifluo-roacetic acid, to obtain the compound of Formula 4 in the form of an acid addition salt.
The reactions of the Reaction Scheme 1 may be performed by reference to the methods disclosed in e.g., Bioorganic & medicinal Chemistry, Vol 16, Issue 5, 2008, 2570-2578.
[166] <Reaction Scheme 2>

[167]

BacHNI 5 OH

BocHNI..

(110 OH
Ra NHBoc
9 [168] In the above Reaction Scheme 2, X is halogen, Boc is an amino-protecting group (for example, tert-butoxycarbonyl), and R2 and R3 are the same as defined in the above.
[169] The compound of Formula 6 may be prepared by coupling the compound of Formula 5 (e.g., an S-isomer) with N,0-dimethylhydroxylamine in the presence of tri-ethylamine, along with the use of hydroxybenzotriazole (HOBt) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDC). The compound of Formula may be prepared by reacting the compound of Formula 7 with a chlorinating agent in the presence of a base (e.g., triethylamine), followed by reacting with R2-NH2. The compound of Fonnula 8 may be dehydrogenated by using n-butyllithium dissolved in hexanes at -78 C under argon atmosphere. After adding the compound of Foiniula thereto, the temperature of the reaction mixture is controlled to -50 C. The reaction mixture is quenched with water to isolate the compound of Formula 9. In an em-bodiment, the magnesium anion of the compound of Formula 6 may be produced by using weakly nucleophilic organomagnesium species such as isopropylmagnesium chloride before the addition to the divalent anion. The compound of Formula 10 may be prepared by reacting the compound of Formula 9 with an acid (e.g., hydrochloric acid) in a solvent (e.g., methanol) and then basifying with a sodium carbonate or ammonium hydroxide solution.
[170] <Reaction Scheme 3>

[1711 RI

VV
N

4 or 10 N' L.R3 11 Neõ...R2 Ro HN
Cy HN
Cy [172] In the above Reaction Scheme 3, X is halogen, and RI, 1Z,,, R3 and Cy are the same as defined in the above.
[173] The compound of Formula 1 may be prepared by coupling the compound of Formula 4 or 10 with 4-chloroquinazoline-6-carbonitrile or 4-chloro-5-fluoroquinazoline in the presence of a base such as triethylamine, N,N-diisopropylethylamine, or ammonia to produce the compound of Formula 12 and then performing the Suzuki reaction with the use of Ri-pyrimidine-5-boronic acid.
[174] And also, the compound of Formula 3 (i.e., the compound having an amino-protecting group) or the compound obtained by introducing an amino-protecting group to the compound of Formula 10 is subject to the Suzuki reaction, followed by removing the amino-protecting group to prepare the compound of Formula 11. And also, the compound of Formula 1 may be prepared by coupling the compound of Formula 11 with 4-chloroquinazoline-6-carbonitrile or 4-chloro-5-fluoroquinazoline in the presence of a base, according to the same methods as in the above. The in-troduction of an amino-protecting group to the compound of Formula 10 may be performed by using an amino-protecting group, such as di-tert-butyl dicarbonate, in the presence of a base such as triethylamine.
[1751 The Suzuki reaction may be carried out typically by using a palladium catalyst. The palladium catalyst includes tetrakis(triphenylphosphine)palladium(0), palladium(II) acetate, dichloro{1,1'-bis(diphenylphosphino)ferrocene}palladium(II), etc. The base includes an inorganic base such as cesium carbonate (Cs2CO3), sodium carbonate (Na2 CO3), potassium carbonate (K2CO3), tripotassium phosphate (K3PO4). The reaction may be performed in a non-polar organic solvent such as toluene or in a polar organic solvent such as 1,4-dioxane, tetrahydrofuran, acetonitrile, 1,2-dimethoxyehane, or N,N -dimethylformamide, at 50 C to 150 C, preferably at 80 C to 110 C. Other reaction conditions, including the reaction time, may be in accordance with known methods regarding the Suzuki reaction.
[176]
[177] The quinazoline derivative according to the present invention, i.e., the compound of Formula 1 or its pharmaceutically acceptable salt has a selective inhibitory activity against the PI3Ko subunit, and therefore can be usefully applied for preventing or treating PI3Kb subunit-mediated diseases, e.g., a respiratory disease, an inflammatory disease, or a proliferative disease, along with avoiding side effects such as lym-phopenia-associated inflammatory responses.
[1781 Therefore, the present invention includes, within its scope, a pharmaceutical com-position for selectively inhibiting phosphatidylinositol 3-kinase delta subunit, comprising a therapeutically effective amount of the compound of Formula 1 or its phaimaceutically acceptable salt as an active ingredient.
[179] For example, the present invention includes, within its scope, a pharmaceutical com-position for preventing or treating a respiratory disease, an inflammatory disease, or a proliferative disease. The respiratory disease and the inflammatory disease include e.g., asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, allergy (or anaphylaxis), psoriasis, rheumatoid arthritis, and autoimmune diseases. The proliferative disease include cancer such as breast cancer, bladder cancer, colorectal cancer, glioma, glioblastoma, lung cancer, hepatocellular carcinoma, stomach cancer, melanoma, thyroid cancer, endometrial cancer, kidney cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, cholangio-carcinoma, ovarian cancer, tuberous sclerosis, alveolar rhabdomyosarcoma, leukemia, and lymphoma.
[180] In an embodiment, the present invention provides a pharmaceutical composition for preventing or treating a proliferative disease. In another embodiment, the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising a therapeutically effective amount of the compound of Formula 1 or its pharmaceutically acceptable salt as an active ingredient. The cancer includes breast cancer, bladder cancer, colorectal cancer, glioma, glioblastoma, lung cancer, hepato-cellular carcinoma, stomach cancer, melanoma, thyroid cancer, endornetrial cancer, kidney cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, cholangiocarcinoma, ovarian cancer, tuberous sclerosis, alveolar rhab-domyosarcoma, leukemia, lymphoma, and so on.
[181] And also, it has been found by the present invention that co-administration of the compound of Fonnula 1 or its pharmaceutically acceptable salt with an immune-checkpoint inhibitor, e.g., a negative regulating antibody of T-lymphocyte activation, exhibits synergistic anticancer activity. The immune-checkpoint inhibitor includes an anti-PDL1 antibody, an anti-PD1 antibody, an anti-CTLA4 antibody, and so on.
[182] Therefore, in still another embodiment, the present invention provides a pharma-ceutical composition for preventing or treating cancer, comprising a therapeutically effective amount of the compound of Formula 1 or its pharmaceutically acceptable salt in combination with a therapeutically effective amount of an immune-checkpoint inhibitor, wherein the combination exhibits synergistic anticancer activity.
The cancer includes breast cancer, bladder cancer, colorectal cancer, glioma, glioblastoma, lung cancer, hepatocellular carcinoma, stomach cancer, melanoma, thyroid cancer, en-dometrial cancer, kidney cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, cholangiocarcinoma, ovarian cancer, tuberous sclerosis, alveolar rhabdomyosarcoma, leukemia, lymphoma, and so on. In the pharmaceutical composition, the compound of Formula 1 or its pharmaceutically acceptable salt and the immune-checkpoint inhibitor may be formulated into a dosage form having a single compartment (i.e., into a same dosage form) or into a dosage form having two or more compartments (i.e., into same dosage forms or into different dosage forms).
The two or more compartments may be the dosage forms administered through the same admin-istration route or through the different administration route. For example, two or more compartments may be the dosage forms administered orally or parenterally, re-spectively.
[183] The pharmaceutical composition of the present invention may comprise a pharma-ceutically acceptable carrier, such as diluents, disintegrants, sweeteners, lubricants, or flavoring agents. The pharmaceutical composition may be formulated to an oral dosage form such as tablets, capsules, powders, granules, suspensions, emulsions, or syrups;
or a parenteral dosage form such as solutions for external use, suspensions for external use, emulsions for external use, gels (e.g., ointment), inhalations, nebulizations, in-jections. The dosage form may be various forms, e.g., dosage forms for single admin-istration or for multiple administrations.

[184] The pharmaceutical composition of the present invention may comprise, for example, a diluent (e.g., lactose, corn starch, etc); a lubricant (e.g., magnesium stearate); an emulsifying agent; a suspending agent; a stabilizer; and/or an isotonic agent.
If necessary, the composition further comprises sweeteners and/or flavoring agents.
[185] The composition of the present invention may be administered orally or parenterally, including inhalant, intravenous, intraperitoneal, subcutaneous, rectal and topical routes of administration. Therefore, the composition of the present invention may be formulated into various forms such as tablets, capsules, aqueous solutions or sus-pensions. In the case of tablets for oral administration, carriers such as lactose, corn starch, and lubricating agents, e.g. magnesium stearate, are conventionally used. In the case of capsules for oral administration, lactose and/or dried corn starch can be used as a diluent. When an aqueous suspension is required for oral administration, the active ingredient may be combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring agents may be used. For intramuscular, in-traperitoneal, subcutaneous and intravenous administration, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous administration, the total concentration of solutes should be controlled in order to render the preparation isotonic. The com-position of the present invention may be in the form of an aqueous solution containing pharmaceutically acceptable carriers, e.g., saline having a pH level of 7.4.
The solutions may be introduced into a patient's intramuscular blood-stream by local bolus injection.
[186] The quinazoline derivative, i.e., the compound of Formula 1 or its pharmaceutically acceptable salt may be administered in a therapeutically effective amount ranging from about 0.0001 mg/kg to about 100 mg/kg per day to a subject patient. Of course, the dosage may be changed according to the patient's age, weight, susceptibility, symptom, or activity of the compound. And also, the immune-checkpoint inhibitor may be ad-ministered in a known therapeutically effective amount of the respective antibody, which may be appropriately controlled by a person skilled in the art.
[187] The present invention includes, within its scope, a method for selectively inhibiting phosphatidylinositol 3-kinase delta subunit in a mammal, comprising administering a therapeutically effective amount of the compound of Formula 1 or its pharmaceutically acceptable salt to the mammal in need thereof.
[188] For example, the present invention includes, within its scope, a method for treating a respiratory disease, an inflammatory disease, or a proliferative disease. The respiratory disease and the inflammatory disease include e.g., asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, allergy (or anaphylaxis), psoriasis, rheumatoid arthritis, and autoimmune diseases. The proliferative disease include cancer such as breast cancer, bladder cancer, colorectal cancer, glioma, glioblastoma, lung cancer, hepatocellular carcinoma, stomach cancer, melanoma, thyroid cancer, endometrial cancer, kidney cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, cholangiocarcinoma, ovarian cancer, tuberous sclerosis, alveolar rhabdomyosarcoma, leukemia, and lymphoma.
[189] In an embodiment, the present invention provides a method for treating a pro-liferative disease, preferably cancer, in a mammal, comprising administering a thera-peutically effective amount of the compound of Formula 1 or its pharmaceutically ac-ceptable salt to the mammal in need thereof. The cancer includes breast cancer, bladder cancer, colorectal cancer, glioma, glioblastoma, lung cancer, hepatocellular carcinoma, stomach cancer, melanoma, thyroid cancer, endometrial cancer, kidney cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, cholangio-carcinoma, ovarian cancer, tuberous sclerosis, alveolar rhabdomyosarcoma, leukemia, lymphoma, and so on.
[190] And also, the present invention provides a method for treating cancer in a mammal, which comprises administering a therapeutically effective amount of the compound of Formula 1 or its pharmaceutically acceptable salt in combination with a therapeutically effective amount of an immune-checkpoint inhibitor to the mammal in need thereof, wherein the combination exhibits synergistic anticancer activity. In the combinatory administration, the respective active ingredients may be administered at the same time or separately; and through the same administration route or through the different ad-ministration routes. The cancer includes breast cancer, bladder cancer, colorectal cancer, glioma, glioblastoma, lung cancer, hepatocellular carcinoma, stomach cancer, melanoma, thyroid cancer, endometrial cancer, kidney cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, cholangio-carcinoma, ovarian cancer, tuberous sclerosis, alveolar rhabdomyosarcoma, leukemia, lymphoma, and so on.
[191] The present invention also provides a use of the compound of Formula 1 or its phar-maceutically acceptable salt for the manufacture of a medicament for selectively in-hibiting phosphatidylinositol 3-kinase delta subunit in a mammal.
[192] For example, the present invention includes, within its scope, a use of the compound of Formula 1 or its pharmaceutically acceptable salt for the manufacture of a medicament for preventing or treating a respiratory disease, an inflammatory disease, or a proliferative disease. The respiratory disease and the inflammatory disease include e.g., asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, allergy (or anaphylaxis), psoriasis, rheumatoid arthritis, and autoimmune diseases. The proliferative disease include cancer such as breast cancer, bladder cancer, colorectal cancer, glioma, glioblastoma, lung cancer, hepatocellular carcinoma, stomach cancer, melanoma, thyroid cancer, endometrial cancer, kidney cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, cholangio-carcinoma, ovarian cancer, tuberous sclerosis, alveolar rhabdomyosarcoma, leukemia, and lymphoma.
[193] In an embodiment, the present invention provides a use of the compound of Fonnula 1 or its pharmaceutically acceptable salt for the manufacture of a medicament for preventing or treating a proliferative disease, preferably cancer. The cancer includes breast cancer, bladder cancer, colorectal cancer, glioma, glioblastoma, lung cancer, hepatocellular carcinoma, stomach cancer, melanoma, thyroid cancer, endometrial cancer, kidney cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, cholangiocarcinoma, ovarian cancer, tuberous sclerosis, alveolar rhabdomyosarcoma, leukemia, lymphoma, and so on.
[194] And also, the present invention provides a use of the compound of Formula 1 or its pharmaceutically acceptable salt in combination with an immune-checkpoint inhibitor for the manufacture of a medicament for preventing or treating cancer. In the com-bination, the respective active ingredients may be administered at the same time or separately; and through the same administration route or through the different admin-istration routes. The cancer includes breast cancer, bladder cancer, colorectal cancer, glioma, glioblastoma, lung cancer, hepatocellular carcinoma, stomach cancer, melanoma, thyroid cancer, endometrial cancer, kidney cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, cholangio-carcinoma, ovarian cancer, tuberous sclerosis, alveolar rhabdomyosarcoma, leukemia, lymphoma, and so on.
[195] The following examples and experimental examples are provided for illustration purposes only, and are not intended to limit the scope of the invention.
[196] The analyses of the compounds prepared in the following Preparations and Examples were carried out as follows: Nuclear magnetic resonance (NMR) spectrum analysis was carried out using Bruker 400 MHz spectrometer and chemical shifts thereof were analyzed in ppm. Column chromatography was carried out on silica gel (Merck, 70-230 mesh). Unless otherwise described, all starting materials were purchased com-mercially and used without further purification. All reactions and chromatographic fractions were analyzed by thin layer chromatography (TLC) on a 250 nm silica gel plate and visualized with ultraviolet or iodine (I2) staining. The product and inter-mediates were purified by flash chromatography or reverse phase HPLC.
[197]
[198] Preparation 1. (S)-2-(1-aminoethyl)-5-chloro-3-phenylquinazolin-4(3H)-one hy-drochloride [199] Step 1. tert-butyl (1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate [200] To a solution of 2-amino-6-chlorobenzoic acid (1.00 g, 7.29 mmol), N-(tert -butoxycarbony1)-L-alanine (1.28 g, 7.29 mmol) in anhydrous pyridine (4 ml), was slowly added triphenyl phosphite (4.8 mL, 18.2 mmol). The reaction mixture was stirred at 70 C for 2 hours and aniline (798 mL, 8.95 mmol) was added thereto. The reaction mixture was stirred at the same temperature for 4 hours and then concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate, washed with a saturated sodium bicarbonate solution two times, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (n-hexane/ethyl acetate =
10/1, v/v) to give 450 mg of the titled compound as a white solid.
[201] Step 2. (S)-2-(1-aminoethyl)-5-chloro-3-phenylquinazolin-4(3H)-one hydrochloride [202] To a solution of tert-butyl (1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-ypethypcarbamate (450 mg, 1.07 mmol) prepared in Step 1 in dichloromethane (5 ml), was slowly added a solution of hydrochloric acid in 1,4-dioxane (4 M, 2 m1). The reaction mixture was stirred at room temperature for 1 hour and then concentrated under reduced pressure. To the resulting residue, was added ethyl acetate. The mixture was stirred at room temperature for 1 hour and then filtered under reduced pressure. The resulting solid was dried to give 490 mg of the titled compound as a white solid. The product was used in the subsequent reaction without further purification.
[203]
[204] Preparations 2 to 4 [205] (S)-2-(1-aminopropy1)-5-chloro-3-phenylquinazolin-4(3H)-one hydrochloride (Preparation 2), (S)-2-(1-aminobuty1)-5-chloro-3-phenylquinazolin-4(3H)-one hy-drochloride (Preparation 3), and (S)-2-(amino(cyclopropypmethyl)-5-chloro-3-phenylquinazolin-4(3H)-one hy-drochloride (Preparation 4) were prepared in accordance with the same procedures as in Preparation 1, using (S)-2-(N-(tert-butoxycarbony1)-amino)butyric acid, N-(tert -butoxycarbony1)-L-norvaline, and (S)-N-Boc-cyclopropylglycine, instead of N-(tert -butoxycarbony1)-L-alanine, respectively.
[206]
[207] Preparation 5. (S)-2-(1-amino-2-methylpropy1)-5-bromo-3-phenylquinazolin-4(3H
)-one hydrochloride [208] The titled compound was prepared in accordance with the same procedures as in Preparation 1, using 2-amino-6-bromobenzoic acid and N-(tert -butoxy-carbony1)-L-valine, instead of 2-amino-6-chlorobenzoic acid and N-(tert -butoxycarbony1)-L-alanine.

[209]
[210] Preparation 6. (S)-2-(1-aminoethyl)-5-chloro-3-cyclopropylquinazolin-4(3H)-one hydrochloride [211] The titled compound was prepared in accordance with the same procedures as in Preparation 1, using cyclopropylamine instead of aniline.
[212]
[213] Preparation 7. (S)-2-(1-aminopropy1)-5-chloro-3-cyclopropylquinazolin-4(3H)-one hydrochloride [214] The titled compound was prepared in accordance with the same procedures as in Preparation 2, using cyclopropylamine instead of aniline.
[215]
[216] Preparation 8. (S)-3-(1-aminoethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one [217] Step 1. 2-chloro-6-methylbenzoyl chloride [218] A solution of 2-chloro-6-methylbenzoic acid (171 mg, 1 mmol), oxalyl chloride (254 mg, 2 mmol), and N,N-dimethylformamide (5 uL) in dichloromethane (3 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to give a residue as a yellow liquid. The residue was used in the subsequent reaction without further purification.
[219] Step 2. 2-chloro-6-methyl-N-phenylbenzamide [220] A solution of aniline (93 mg, 1.1 mmol), triethylamine (202 mg, 2 mmol) in dichloromethane (3 mL) was strirred at room temperature for 10 minutes.
2-Chloro-6-methylbenzoyl chloride (202 mg, 2 mmol) prepared in Step 1 was slowly added to the solution, which was then stirred at room temperature for 1 hour.
Water (3mL) was added to the reaction mixture, which was then extracted with dichloromethane. The resulting extract was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. To the resulting residue, was added n -heptane. The mixture was stirred at room temperature for 30 minutes and then filtered under reduced pressure. The resulting solid was dried to give 214 mg of the titled compound as a white solid. (Yield: 87%) [221] Step 3. tert-butyl (S)-(1-(methoxy(methypamino)-1-oxopropan-2-yl)carbamate [222] While a mixture of N-(tert-butoxycarbony1)-L-alanine (1 g, 5.3 mmol), triethylamine (2.9 mL, 21.1 mmol) and hydroxybenzotriazole (135 mg, 5.3 mmol) in anhydrous dichloromethane (20 mL) was stirred at 0 C, 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (384.3 mg, 10.9 mmol) was slowly added thereto over 30 minutes. The reaction mixture was stirred at room temperature for 30 minutes and then N, 0-dimethylhydroxylamine hydrochloride (568.7 mg, 5.8 mmol) was added thereto. The reaction mixture was stirred at room temperature for 20 hours and then quenched by water (100 mL). The organic layer was washed with water (2 x 1L) and brine (500 mL), dried over anhydrous magnesium sulfate, filtered, and then concentrated under reduced pressure. The resulting residue was slurried in petroleum ether (200 mL), stirred at room temperature for 10 minutes, and then filtered. The resulting solid was dried in vacuo to give 1.1 g of the titled compound as a white solid.
[223] Step 4. tert-butyl (S)-(4-(3-chloro-2-(phenylcarbamoyl)pheny1)-3-oxobutan-2-yl)carbamate [224] A solution of 2-chloro-6-methyl-N-phenylbenzamide (246 mg, 1 mmol) prepared in Step 2 in anhydrous tetrahydrofuran (3 mL) was cooled to -78 C and then a solution of n-butyllithium in hexane (2.5 M, 1 mL) was slowly added thereto over 20 minutes. The reaction mixture was stirred at the same temperature for 2 hours. A solution of tert-butyl (S)-(1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate (370 mg, 1.5 mmol) prepared in Step 3 in anhydrous tetrahydrofuran (5 mL) was added at -78 C to the reaction mixture. Then, a solution of isopropylmagnesium chloride in tetrahy-drofuran (0.9 mL) was slowly added to the reaction mixture for 20 minutes. The reaction mixture was stirred at the same temperature for 2 hours and then the reaction temperature thereof was increased to -50 C. The reaction mixture was quenched by water (3 mL) and then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (n-hexane/ethyl acetate = 2/1, v/v) to give 185 mg of the titled compound as a colorless liquid. The product was used in the subsequent reaction without further purification.
[225] Step 5. (S)-3-(1-aminoethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one [226] To a solution of tert-butyl (S)-(4-(3-chloro-2-(phenylcarbamoyl)pheny1)-3-oxobutan-2-y1)carbamate (390 mg, 0.9 mmol) prepared in Step 4 in methanol (3 mL), was slowly added hydrochloric acid (1 mL) at room temperature. The reaction mixture was stirred at 60 C for 3 hours, controlled to pH 9-10 with a saturated ammonium hydroxide solution, and then extracted with dichloromethane. The extract was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol = 20/1, v/v) to give 189 mg of the titled compound as a white solid. (Yield: 67%) [227]
[228] Preparation 9. (S)-3-(1-aminoethyl)-8-chloro-2-(4-fluorophenypisoquinolin-1(2H
)-one [229] The titled compound was prepared in accordance with the same procedures as in Preparation 8, using 4-fluoroaniline instead of aniline.
[230]

[231] Preparations 10 and 11 [232] (S)-3-(1-aminopropy1)-8-chloro-2-phenylisoquinolin-1(2H)-one (Preparation 10) and (S)-3-(1-amino-2-methylpropy1)-8-chloro-2-phenylisoquinolin-1(2H)-one (Preparation
11) were prepared in accordance with the same procedures as in Preparation 8, using (S)-2-(N-(tert-butoxycarbony1)-amino)butyric acid and N-(tert -butoxy-carbony1)-L-valine, instead of N-(tert-butoxycarbony1)-L-alanine, respectively.
[233]
[234] Preparation 12. (S)-44(1-(5-chloro-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile [235] To a solution of (S)-2-(1-aminoethyl)-5-chloro-3-phenylquinazolin-4(3H)-one hy-drochloride (16.9 mg, 0.052 mmol) prepared in Preparation 1 and 4-chloroquinazoline-6-carbonitrile (10 mg, 0.052 mmol) in isopropyl alcohol (1 mL), was slowly added N,N-diisopropylethylamine (28 uL, 0.16 mmol). The reaction mixture was stirred at 80 C for 2 hours, cooled to room temperature, and then con-centrated under reduced pressure. The residue in a yellow liquid was purified by silica gel column chromatography (n-hexane/ethyl acetate = 1/1, v/v) to give 14 mg of the titled compound as a white solid.
[236] 1H-NMR (400MHz, CDC13) 8 8.63(s, 1H), 8.27(s, 1H), 7.88(s, 2H), 7.64-7.57(m, 5H), 7.50(m, 2H), 7.40(m, 1H), 7.29(m, 1H), 5.24(m, 1H), 1.52(d, 3H) [237]
[238] Preparations 13 to 18 [239] The titled compounds of Preparations 13 to 18 were prepared in accordance with the same procedures as in Preparation 12, using the compounds prepared in Preparations 2 to 7, instead of (S)-2-(1-aminoethyl)-5-chloro-3-phenylquinazolin-4(3H)-one hy-drochloride, respectively.
[240]
[241] Preparation 13. (S)-4-((1-(5-chloro-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)amino)quinazoline-6-carbonitrile [242] 'H-NMR (400MHz, CDC13) 8 8.61(s, 1H), 8.30(s, 1H), 7.90(s, 2H), 7.63(m, 5H), 7.55(m, 1H), 7.48(m, 2H), 7.04(d, 1H), 5.27(m, 1H), 2.03(m, 1H), 1.85(m, 1H), 0.86(t, 3H) [243]
[244] Preparation 14. (S)-4-((1-(5-chloro-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yDbutypamino)quinazoline-6-carbonitrile [245] 1H-NMR (400MHz, CDC13) 8 8.63(s, 1H), 8.32(s, 1H), 7.90(s, 2H), 7.64-7.57(m, 51-I), 7.50(m, 2H), 7.39(d, 1H), 6.97(d, 1H), 5.35(m, 1H), 1.86(m, 2H), 1.36(m, 1H), 1.24(m, 1H), 0.68(1, 3H) [246]

[247] Preparation 15. (S)-4-(((5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin -2-y1)(cyclopropyl)methyl)amino)quinazoline-6-carbonitrile [248] 11-1-NMR (400MHz, CDC13) 8 8.60(s, 1H), 8.27(s, 1H), 7.90(s, 2H), 7.63(d, 2H), 7.58(m, 3H), 7.50(m, 2H), 7.46(m, 1H), 6.97(d, 1H), 4.98(m, 1H), 1.36(m, 1H), 0.58(m, 2H), 0.35(m, 1H), 0.12(m, 1H) [249]
[250] Preparation 16. (S)-4-((1-(5-bromo-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-y1)-2-methylpropyl)amino)quinazoline-6-carbonitril [251] 'H-NMR (400MHz, CDC13) 8 8.59(s, 1H), 8.26(s, 1H), 7.91(s, 2H), 7.74(m, 2H), 7.61(m, 4H), 7.39(m, 1H), 7.30(m, 1H), 6.77(d, 1H), 5.44(m, 1H), 2.26(m, 1H), 0.99(d, 3H), 0.83(d, 3H) [252]
[253] Preparation 17. (S)-4-41-(5-chloro-3-cyclopropy1-4-oxo -3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile [254] 'H-NMR (400MHz, CDC13) 8 8.74(s, 1H), 8.28(s, 1H), 7.93(s, 2H), 7.62(d, 2H), 7.47(m, 1H), 7.42(m, 1H), 6.33(m, 1H), 3.09(m, 1H), 1.71(d, 3H), 1.48(m, 2H), 1.12(m, 1H), 1.01(m, 1H) [255]
[256] Preparation 18. (S)-44(1-(5-chloro-3-cyclopropy1-4-oxo -3,4-dihydroquinazolin-2-yl)propyl)amino)quinazoline-6-carbonitrile [257] 11-1-NMR (400MHz, CDC13) 8 8.73(s, 1H), 8.36(s, 1H), 7.92(s, 2H), 7.57(m, 2H), 7.46(m, 1H), 7.26(m, 1H), 6.39(m, 1H), 3.10(m, 1H), 2.19(m, 1H), 2.00(m, 1H), 1.49(m, 2H), 1.06(t, 3H), 0.88(m, 2H) [258]
[259] Preparations 19 to 22 [260] The titled compounds of Preparations 19 to 22 were prepared in accordance with the same procedures as in Preparation 12, using 4-chloro-5-fluoroquinazoline instead of 4-chloroquinazoline-6-carbonitrile; and the compounds prepared in Preparations 1, 2, 4, and 5, instead of (S)-2-(1-aminoethy1)-5-chloro-3-phenylquinazolin-4(3H)-one hy-drochloride, respectively.
[261]
[262] Preparation 19. (S)-5-chloro-2-(1-((5-fluoroquinazolin -4-yl)amino)ethyl)-3-phenylquinazolin-4(3H)-one [263] 11-1-NMR (400MHz, CDC13) 8 8.49(s, 1H), 7.83(m, 1H), 7.61(m, 7H), 7.49(m, 2H), 7.38(m, 1H), 7.13(m, 1H), 5.21(m, 1H), 1.48(d, 3H) [264]
[265] Preparation 20. (S)-5-chloro-2-(1-((5-fluoroquinazolin -4-yl)amino)propy1)-3-phenylquinazolin-4(3H)-one [266] 'H-NMR (400MHz, CDC13) 8 8.47(s, 1H), 7.66-7.57(m, 7H), 7.48(m, 2H), 7.37(m, 1H), 7.14(m, 1H), 5.22(m, 1H), 1.97(m, 1H), 1.77(m, 1H), 0.87(t, 3H) [267]
[268] Preparation 21. (S)-5-chloro-2-(cyclopropyl((5-fluoroquinazolin -4-yl)amino)methyl)-3-phenylquinazolin-4(3H)-one [269] 11-1-NMR (400MHz, CDC13) 8 8.46(s, 1H), 7.68-7.51(m, 9H), 7.48(m, 1H), 7.43(m, 1H), 7.20(m, 1H), 4.97(m, 1H), 1.32(m, 1H), 0.53(m, 2H), 0.37(m, 1H), 0.21(m, 1H) [270]
[271] Preparation 22. (S)-5-bromo-2-(1-((5-fluoroquinazolin-4-yl )amino)-2-methylpropy1)-3-phenylquinazolin-4(3H)-one [272] 'H-NMR (400MHz, CDC13) 8 8.58(s, 1H), 7.72(m, 1H), 7.71-7.45(m, 6H), 7.36(m, 2H), 7.15(m, 2H), 7.14(m, 1H), 5.39(m, 1H), 2.21(m, 1H), 0.99(d, 3H), 0.82(d, 3H) [273]
[274] Preparations 23 to 25 [275] The titled compounds of Preparations 23 to 25 were prepared in accordance with the same procedures as in Preparation 12, using the compounds prepared in Preparations 8 to 10, instead of (S)-2-(1-aminoethyl)-5-chloro-3-phenylquinazolin-4(3H)-one hy-drochloride, respectively.
[276]
[277] Preparation 23. (S)-44(1-(8-chloro-1-oxo -2-pheny1-1,2-dihydroisoquinolin-3-yl)ethyl)amino)quinazoline-6-carbonitrile [278] 111-NMR (400MHz, CDC13) 8 8.55(s, 1H), 8.35(s, 1H), 7.85(m, 2H), 7.31(m, 3H), 7.10(m, 1H), 7.05(m, 4H), 6.78(br, 1H), 6.62(s, 1H), 5.06(m, 1H), 1.50(d, 3H) [279]
[280] Preparation 24. (S)-44(1-(8-chloro-2-(4-fluoropheny1)-1-oxo -1,2-dihydroisoquinolin-3-ypethypamino)quinazoline-6-carbonitrile [281] 'H-NMR (400MHz, CDC13) 8.57(s, 1H), 8.44(s, 1H), 7.95-7.80(m, 2H), 7.48-7.39(m, 3H), 7.33-7.29(m, 2H), 7.20(m, 1H), 6.91(m, 1H), 6.73(d, 1H), 6.62(s, 1H), 5.06-5.01(m, 1H), 1.52(d, 3H) [282]
[283] Preparation 25. (S)-44(1-(8-chloro-1-oxo -2-pheny1-1,2-dihydroisoquinolin-3-yl)propyl)amino)quinazoline-6-carbonitrile [284] 'H-NMR (400MHz, Me0D) 8 8.85(s, 1H), 8.47(s, 1H), 8.02(d, 1H), 7.81(d, 1H), 7.62-7.43(m, 9H), 6.83(s, 1H), 4.94(m, 1H), 2.18(m, 1H), 1.94(m, 1H), 0.90(t, 3H) [285]
[286] Preparations 26 and 27 [287] The titled compounds of Preparations 26 and 27 were prepared in accordance with the same procedures as in Preparation 12, using 4-chloro-5-fluoroquinazoline instead of 4-chloroquinazoline-6-carbonitrile; and the compounds prepared in Preparations 8 and 11, instead of (S)-2-(1-aminoethyl)-5-chloro-3-phenylquinazolin-4(3H)-one hy-drochloride, respectively.
[288]
[289] Preparation 26. (S)-8-chloro-3-(1-((5-fluoroquinazolin -4-yl)amino)ethyl)-2-phenylisoquinolin-1(2H)-one [290] 'H-NMR (400MHz, CDC13) 8.50(s, 1H), 7.64(m, 2H), 7.50(m, 2H), 7.44(m, 2H), 7.37-7.30(m, 4H), 7.17-7.12(m, 1H), 6.67(m, 1H), 6.60(s, 1H), 5.06(m, 1H), 1.50(d, 3H) [291]
[292] Preparation 27. (S)-8-chloro-3-(1-((5-fluoroquinazolin-4-y1 )amino)-2-methylpropy1)-2-phenylisoquinolin-1(2H)-one [293] 'H-NMR (400MHz, CDC13) 8 8.55(s, 1H), 7.66(m, 3H), 7.57(m, 2H), 7.48(m, 1H), 7.35(m, 2H), 7.20(m, 2H), 7.15(m, 1H), 6.88(m, 1H), 6.45(s, 1H), 4.97(m, 1H), 1.00(d, 3H), 0.88(d, 3H) [294]
[295] Example 1. (S)-4((144-oxo-3-phenyl-5-(pyrimidin-5-y1 )-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile [296] To a mixture of (S)-4-((1-(5-chloro-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoli ne-6-carbonitrile (15 mg, 0.03 mmol) prepared in Preparation 12, pyrimidine-5-boronic acid (5.6 mg, 0.045 mmol), a 2N sodium carbonate solution (400 uL), and tetrakis(triphenylphosphine)palladium(0) (1.9 mg, 5 mol%), was slowly added 1,4-dioxane (1 mL). The reaction mixture was refluxed under stirring at 96 C
overnight and then cooled to room temperature. Distilled water was added to the reaction mixture, which was then extracted with dichloromethane. The extract was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to give a residue as a yellow liquid. The residue was purified by silica gel column chro-matography (dichloromethane/methanol = 9/1, v/v) to give 8.9 mg of the titled compound as a pale yellow solid.
[297] 'H-NMR (400MHz, CDC13) ô 9.14(s, 1H), 8.71(s, 2H), 8.64(s, 1H), 8.29(s, 1H), 7.88(m, 3H), 7.85(s, 1H), 7.57(m, 2H), 7.50(m, 2H), 7.33(m, 3H), 5.26(m, 1H), 1.58(d, 3H) [298] Examples 2 to 47 [299] The titled compounds of Examples 2 to 47 were prepared in accordance with the same procedures as in Example 1, using the compounds prepared in Preparation
12 to 27; and the corresponding substituted or unsubstituted pyrimidine-5-boronic acid.

[300]
[301] Example 2. (S)-44(1-(5-(2-aminopyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-ypethyl)amino)quinazoline-6-carbonitrile [302] 'H-NMR (400MHz, CDC13) 8 8.64(s, 1H), 8.29(s, 3H), 7.86(s, 2H), 7.80(m, 2H), 7.60-7.52(m, 4H), 7.47(m, 2H), 7.29(m, 1H), 5.24(m, 1H), 5.07(s, 2H), 1.55(d, 3H);
(Yield: 54%) [303]
[304] Example 3. (S)-44(1-(542-methylpyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile [305] 'H-NMR (400MHz, CDC13) 8 8.64(s, 1H), 8.60(s, 2H), 8.29(s, 1H), 7.87(m, 4H), 7.59(m, 3H), 7.45(m, 1H), 7.30(m, 3H), 5.26(m, 1H), 2.73(s, 3H), 1.53(d, 3H);
(Yield:
52%) [306]
[307] Example 4. (S)-44(1-(4-oxo-3-pheny1-5-(pyrimidin-5-y1 )-3,4-dihydroquinazolin-2-yl)propyl)amino)quinazoline-6-carbonitrile [308] 'H-NMR (400MHz, CDC13) 8 9.13(s, 1H), 8.69(s, 2H), 8.63(s, 1H), 8.30(s, 1H), 7.92(s, 2H), 7.90-7.82(m, 2H), 7.62-7.53(m, 3H), 7.43-7.35(m, 1H), 7.34-7.28(m, 2H), 6.99(d, 1H), 5.32-5.24(m, 1H), 2.04-1.98(m, 1H), 1.89-1.75(m, 1H), 0.88(t, 3H); (Yield: 65%) [309]
[310] Example 5. (S)-44(1-(542-methoxypyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)amino)quinazoline-6-carbonitrile [311] 11-1-NMR (400MHz, CDC13) 8 8.62(s, 1H), 8.46(s, 2H), 8.34(s, 1H), 7.91(s, 2H), 7.84-7.81(m, 2H), 7.62-7.53(m, 3H), 7.43-7.37(m, 1H), 7.32-7.27(m, 2H), 7.12(d, 1H), 5.29-5.24(m, 1H), 4.00(s, 3H), 2.05-1.96(m, 1H), 1.89-1.76(m, 1H), 0.88(t, 3H);
(Yield: 51%) [312]
[313] Example 6. (S)-44(145-(2-ethoxypyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)amino)quinazoline-6-carbonitrile [314] 'H-NMR (400MHz, CDC13) 8 8.62(s, 1H), 8.45(s, 2H), 8.32(s, 1H), 7.91(s, 2H), 7.85-7.80(m, 2H), 7.61-7.52(m, 3H), 7.40(d, 1H), 7.34-7.27(m, 2H), 7.06(d, 1H), 5.31-5.25(m, 1H), 4.41(q, 2H), 2.05-1.98(m, 1H), 1.85-1.78(m, 1H), 1.42(t, 3H), 0.88(t, 3H); (Yield: 67%) [315]
[316] Example 7. (S)-4-01-(5-(2-(dimethylamino)pyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)amino)quinazoline-6-carbonitrile [317] 'H-NMR (400MHz, CDC13) 8 8.61(s, 1H), 8.31(s, 1H), 8.29(s, 2H), 7.91(s, 2H), 7.83-7.74(m, 2H), 7.60-7.51(m, 3H), 7.38-7.34(m, 1H), 733-7.27(m, 2H), 7.13(d, 1H), 5.30-5.26(m, 1H), 3.17(s, 6H), 2.05-1.96(m, 1H), 1.83-1.76(m, 1H), 0.88(t, 3H);
(Yield: 60%) [318]
[319] Example 8. (S)-4-01-(5-(2-(methylsulfanyppyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yepropyeamino)quinazoline-6-carbonitrile [320] 'H-NMR (400MHz, CDC13) 8 8.62(s, 1H), 8.48(s, 2H), 8.35(s, 1H), 7.91(s, 2H), 7.83(d, 2H), 7.60-7.52(m, 3H), 7.43-7.39(m, 1H), 7.31-7.26(m, 2H), 7.14(d, 1H), 5.28-5.24(m, 1H), 2.55(s, 3H), 2.04-1.95(m, 1H), 1.88-1.77(m, 1H), 0.88(t, 3H);
(Yield: 44%) [321]
[322] Example 9. (S)-4-((1-(5-(2-methylpyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yl)butyl)amino)quinazoline-6-carbonitrile [323] 'H-NMR (400MHz, CDC13) ô 8.64(s, 1H), 8.59(s, 2H), 8.33(s, 1H), 7.91(s, 2H), 7.82(m, 2H), 7.61(m, 3H), 7.56(m, 1H), 7.30(m, 2H), 6.98(d, 1H), 5.38(m, 1H), 2.73(s, 3H), 1.84(m, 2H), 1.34(m, 1H), 1.13(m, 1H), 0.69(t, 3H); (Yield: 51%) [324]
[325] Example 10. (S)-4-((1-(5-(2-methoxypyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yDbutypamino)quinazoline-6-carbonitrile [326] 11-1-NMR (400MHz, CDC13) 8 8.64(s, 1H), 8.46(s, 2H), 8.30(s, 1H), 7.91(s, 2H), 7.80(m, 2H), 7.59(m, 3H), 7.46(m, 1H), 7.30(m, 2H), 6.94(d, 1H), 5.37(m, 1H), 4.00(s, 3H), 1.84(m, 2H), 1.36(m, 1H), 1.24(m, 1H), 0.69(t, 3H); (Yield: 74%) [327]
[328] Example 11. (S)-44(1-(5-(2-ethoxypyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yl)butyl)amino)quinazoline-6-carbonitrile [329] 'H-NMR (400MHz, CDC13) 8 8.64(s, 1H), 8.44(s, 2H), 8.31(s, 1H), 7.91(s, 2H), 7.80(m, 2H), 7.62-7.55(m, 3H), 7.45(d, 1H), 7.30(m, 2H), 6.93(d, 1H), 5.38(m, 1H), 4.42(q, 2H), 1.84(m, 2H), 1.42(t, 3H), 1.36(m, 1H), 1.26(m, 1H), 0.69(t, 3H);
(Yield:
51%) [330]
[331] Example 12. (S)-44(1-(5-(2-aminopyrimidin-5-y1)-4-oxo -3-pheny1-3,4-dihydroquinazolin-2-yDbutypamino)quinazoline-6-carbonitrile [332] 'H-NMR (400MHz, CDC13) ô 8.65(s, 1H), 8.35(s, 1H), 8.28(s, 2H), 7.91(s, 2H), 7.78(m, 2H), 7.63-7.55(m, 3H), 7.45(d, 1H), 7.33(m, 2H), 7.00(d, 1H), 5.38(m, 1H), 5.04(s, 2H), 1.85(m, 2H), 1.36(m, 1H), 1.24(m, 1H), 0.68(t, 3H); (Yield: 54%) [333]
[334] Example 13. (S)-4-((1-(5-(2-aminopyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-y1)-2-methylpropyl)amino)quinazoline-6-carbonitril [335] 'H-NMR (400MHz, CDC13) b 8.59 (s, 1H), 8.29 (s, 1H), 8.26 (s, 2H), 7.91 (s, 2H), 7.83-7.80 (m, 2H), 7.59-7.51 (m, 3H), 7.35-7.26 (m, 3H), 6.88 (d, 1H), 5.47-5.43 (m, 1H), 5.14 (brs, 2H), 2.34-2.23 (m, 1H), 1.01 (d, 3H), 0.84 (d, 3H); (Yield:
53%) [336]
[337] Example 14. (S)-4-((cyclopropy1(4-oxo-3-phenyl-5-(pyrimidin-5-y1 )-3,4-dihydroquinazolin-2-yl)methyl)amino)quinazoline-6-carbonitrile [338] 11-1-NMR (400MHz, CDC13) 8 9.13(s, 1H), 8.70(s, 2H), 8.60(s, 1H), 8.32(s, 1H), 7.89(s, 2H), 7.86(m, 2H), 7.57(m, 2H), 7.49(m, 2H), 7.30(m, 1H), 7.13(d, 1H), 4.95(m, 1H), 1.39(m, 1H), 0.60(m, 2H), 0.40(m, 1H), 0.18(m, 1H); (Yield: 51%) [339]
[340] Example 15. (S)-4-((cyclopropy1(5-(2-methoxypyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yl)methyl)amino)quinazoline-6-carbonitrile [341] 'H-NMR (400MHz, CDC13) ô 8.59(s, 1H), 8.47(s, 2H), 8.39(s, 1H), 7.86(m, 2H), 7.80(m, 2H), 7.67(m, 3H), 7.53(m, 1H), 7.48(m, 1H), 7.36(m, 1H), 7.27(m, 1H), 4.91(m, 1H), 3.99(s, 3H), 1.42(m, 1H), 0.58(m, 2H), 0.39(m, 1H), 0.19(m, 1H);
(Yield:
65%) [342]
[343] Example 16. (S)-4-((cyclopropy1(5-(2-ethoxypyrimidin-5-y1)-4-oxo -3-phenyl-3,4-dihydroquinazolin-2-yl)methyl)amino)quinazoline-6-carbonitrile [344] 'H-NMR (400MHz, CDC13) 8 8.45(s, 1H), 8.31(s, 2H), 7.90(s, 1H), 7.81(m, 2H), 7.80(m, 2H), 7.56(m, 3H), 7.47(m, 1H), 7.35(m, 1H), 7.27(m, 1H), 7.13(d, 1H), 4.97(m, 1H), 4.42(q, 2H), 1.40(t, 3+1H), 0.58(m, 2H), 0.40(m, 1H), 0.19(m, 1H);
(Yield: 51%) [345]
[346] Example 17. (S)-44(1-(3-c yclopropy1-4-oxo-5-(pyrimidin-5-y1 )-3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile [347] 11-1-NMR (400MHz, CDC13) 8 9.23(s, 1H), 8.74(s, 1H), 8.71(s, 2H), 8.33(s, 1H), 7.92(s, 2H), 7.82(m, 2H), 7.53(m, 1H), 7.28(m, 1H), 6.37(m, 1H), 3.04(m, 1H), 1.74(d, 3H), 1.44(m, 2H), 1.13(m, 1H), 0.89(m, 1H); (Yield: 61%) [348]
[349] Example 18. (S)-4-41-(3-cyclopropyl-5-(2-methoxypyrimidin-5-y1)-4-oxo -3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile [350] 11-1-NMR (400MHz, CDC13) 8 8.74(s, 1H), 8.49(s, 2H), 8.34(s, 1H), 7.91(s, 2H), 7.78(d, 2H), 7.61(d, 1H), 7.27(m, 1H), 6.36(m, 1H), 4.08(s, 3H), 3.04(m, 1H), 1.74(d, 3H), 1.42(m, 2H), 1.14(rn, 1H), 0.90(m, 1H); (Yield: 34%) [351]
[352] Example 19. (S)-4-((1-(3-c yclopropy1-5-(2-ethoxypyrimidin-5-y1)-4-oxo -3,4-dihydroquinazolin-2-yl)ethyl)amino)quinazoline-6-carbonitrile [353] 'H-NMR (400MHz, CDC13) b 8.74(s, 1H), 8.47(s, 2H), 8.34(s, 1H), 7.91(s, 2H), 7.77(s, 2H), 7.62(d, 1H), 7.27(m, 1H), 6.36(m, 1H), 4.50(q, 2H), 3.04(m, 1H), 1.74(d, 3H), 1.47(t, 3H), 1.41(m, 2H), 1.14(m, 1H), 0.90(m, 1H); (Yield: 56%) [354]
[355] Example 20. (S)-44(1-(3-cyclopropy1-4-oxo-5-(pyrimidin-5-y1 )-3,4-dihydroquinazolin-2-yl)propyl)amino)quinazoline-6-carbonitrile [356] 11-1-NMR (400MHz, CDC13) 8 9.23(s, 1H), 8.73(s, 1H), 8.70(s, 2H), 8.38(s, 1H), 7.93(s, 2H), 7.79(s, 2H), 7,27(m, 1H), 6.23(m, 1H), 3.05(m, 1H), 2.21(m, 1H), 2.07(m, 1H), 1.45(m, 2H), 1.18(m, 1H), 1.09(t, 3H), 0,85(m, 1H); (Yield: 51%) [357]
[358] Example 21. (S)-44(1-(5-(2-aminopyrimidin-5-y1)-3-cyclopropy1-4-oxo -3,4-dihydroquinazolin-2-yepropypamino)quinazoline-6-carbonitrile [359] 'H-NMR (400MHz, CDC13) ô 8.73(s, 1H), 8.37(s, 1H), 8.29(s, 2H), 7.93(d, 2H), 7.71(m, 2H), 7.41(m, 1H), 7.26(m, 1H), 6.41(m, 1H), 5.22(s, 2H), 3.05(m, 1H), 2.22(m, 1H), 2.04(m, 1H), 1.44(m, 2H), 1.16(m, 1H), 1.08(t, 3H), 0.86(m, 1H);
(Yield:
50%) [360]
[361] Example 22. (S)-2-(1-((5-fluoroquinazolin-4-y1 )amino)ethyl)-3-phenyl-5-(pyrimidin-5-yl)quinazolin-4(3H)-one [362] 'H-NMR (400MHz, CDC13) 8 9.15(s, 1H), 8.65(s, 2H), 8.46(s, 1H), 7.83(m, 3H), 7.63(m, 2H), 7.55(m, 3H), 7.45(m, 1H), 7.31(m, 1H), 7.18(m, 1H), 5.23(m, 1H), 1.52(d, 3H); (Yield: 61%) [363]
[364] Example 23. (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin -4-yl)amino)ethyl)-3-phenylquinazolin-4(3H)-one [365] 11-1-NMR (400MHz, CDC13) 8 8.48(s, 1H), 8.28(s, 2H), 7.95(m, 1H), 7.79(m, 2H), 7.64(m, 2H), 7.55(m, 3H), 7.43(m, 1H), 7.31(d, 1H), 7.26(m, 1H), 7.17(m, 1H), 5.24(m, 1H), 5.07(s, 2H), 1.50(d, 3H); (Yield: 69%) [366]
[367] Example 24. (S)-2-(1-((5-fluoroquinazolin-4-yDamino)propyl )-3-phenyl-5-(pyrimidin-5-yl)quinazolin-4(3H)-one [368] 'H-NMR (400MHz, CDC13) ô 9.12(s, 1H), 8.69(s, 2H), 8.48(m, 1H), 7.86(m, 2H), 7.64(m, 3H), 7.55(m, 3H), 7.44(m, 1H), 7.28(m, 2H), 7.17(m, 1H), 5.22(m, 1H), 2.04(m, 1H), 1.82(m, 1H), 0.90(t, 3H); (Yield: 64%) [369]
[370] Example 25. (S)-5-(2-aminopyrimidin-5-y1)-2-(1-((5-fluoroquinazolin -4-yl)amino)propy1)-3-phenylquinazolin-4(3H)-one [371] 11-1-NMR (400MHz, CDC13) 8 8.47(s, 1H), 8.28(s, 3H), 7.77(m, 1H), 7.64(m, 3H), 7.56(m, 3H), 7.45(m, 1H), 7.32(m, 1H), 7.27(m, 1H), 7.18(m, 1H), 5.23(m, 1H), 5.19(s, 2H), 2.00(m, 1H), 1.81(m, 1H), 0.88(t, 3H); (Yield: 70%) [372]
[373] Example 26. (S)-5-(2-fluoropyrimidin-5-y1)-2-(1-((5-fluoroquinazolin -4-yl)amino)propy1)-3-phenylquinazolin-4(3H)-one [374] '1-1-NMR (400MHz, CDC13) 8 8.47(s, 1H), 8.20(br, 1H), 7.79(m, 2H), 7.65-7.55(m, 6H), 7.45(m, 1H), 7.30(m, 1H), 7.24(m, 2H), 7.15(m, 1H), 5.23(m, 1H), 1,99(m, 1H), 1.79(m, 1H), 0.88(t, 3H); (Yield: 64%) [375]
[376] Example 27. (S)-2-(14(5-fluoroquinazolin-4-yDamino)propyl )-5-(2-methylpyrimidin-5-y1)-3-phenylquinazolin-4(3H)-one [377] '1-1-NMR (400MHz, CDC13) 8 8.59(s, 2H), 8.48(s, 1H), 7.82(m, 2H), 7.65(m, 2H), 7.54(m, 4H), 7.44(m, 1H), 7.27(m, 2H), 7.15(m, 1H), 5.23(m, 1H), 2.72(s, 3H), 2.04(m, 1H), 1.79(m, 1H), 0.89(t, 3H); (Yield: 51%) [378]
[379] Example 28. (S)-2-(1-((5-fluoroquinazolin-4-yDamino)-2-methylpropyl )-3-phenyl-5-(pyrimidin-5-yl)quinazolin-4(3H)-one [380] 1H-NMR (400MHz, CDC13) 8 9.12(s, 1H), 8.69(s, 2H), 8.46(s, 1H), 7.88-7.78(m, 2H), 7.70-7.60(m, 2H), 7.60-7.47(m, 4H), 7.39(d, 1H), 7.31-7.24(m, 2H), 7.20-7.14(m, 1H), 5.41-5.37(m, 1H), 2.28-2.19(m, 1H), 1.03(d, 3H), 0.84(d, 3H);
(Yield: 65%) [381]
[382] Example 29. (S)-5-(2-aminopyrimidin-5-y1)-2-(14(5-fluoroquinazolin -4-yl)amino)-2-methylpropy1)-3-phenylquinazolin-4(3H)-one [383] 'H-NMR (400MHz, CDC13) 8 8.45(s, 1H), 8.26(s, 2H), 7.80-7.73(m, 2H), 7.67-7.60(m, 2H), 7.59-7.51(m, 4H), 7.38-7.34(m, 1H), 7.32-7.28(m, 1H), 7.25-7.23(m, 1H), 7.19-7.13(m, 1H), 5.41-5.37(m, 1H), 5.26(brs, 2H), 2.27-2.18(m, 111), 1.02(d, 3H), 0.83(d, 3H); (Yield: 50%) [384]
[385] Example 30. (S)-2-(cyclopropy1((5-fluoroquinazolin-4-y1 )amino)methyl)-3-phenyl-5-(pyrimidin-5-yl)quinazolin-4(3H)-one [386] '1-1-NMR (400MHz, CDC13) ô 9.12(s, 1H), 8.70(s, 2H), 8.50(s, 1H), 7.82(m, 2H), 7.65(m, 3H), 7.53(m, 4H), 7.34(m, 1H), 7.26(m, 1H), 7.18(m, 1H), 4.97(m, 1H), 1.37(m, 1H), 0.55(m, 2H), 0.42(m, 1H), 0.22(m, 1H); (Yield: 64%) [387]
[388] Example 31. (S)-5-(2-aminopyrimidin-5-y1)-2-(cyclopropy1( (5-fluoroquinazolin-4-yl)amino)methyl)-3-phenylquinazolin-4(3H)-one [389] 11-1-NMR (400MHz, CDC13) 8 8.45(s, 1H), 8.28(s, 2H), 7.75(m, 2H), 7.62(m, 2H), 7.53(m, 3H), 7.47(m, 1H), 7.35(m, 1H), 7.24(m, 2H), 7.16(m, 1H), 5.07(s, 2H), 4.99(m, 1H), 1.36(m, 1H), 0.54(m, 2H), 0.42(m, 1H), 0.22(m 1H); (Yield: 54%) [390]
[391] Example 32. (S)-44(1-(1-oxo-2-pheny1-8-(pyrimidin-5-y1 )-1,2-dihydroisoquinolin-3-yl)ethyl)amino)quinazoline-6-carbonitrile [392] '1-1-NMR (400MHz, CDC13) 8 9.35(s, 1H), 9.06(s, 1H), 9.00(s, 2H), 8.67(s, 1H), 8.56(s, 1H), 8.28(m, 1H), 7.89(m, 1H), 7.68-7.62(m, 2H), 7.34(m, 1H), 7.24(m, 4H), 6.74(s, 1H), 6.30(d, 1H), 5.09(m, 1H), 1.55(d, 3H); (Yield: 58%) [393]
[394] Example 33. (S)-44(1-(8-(2-methoxypyrimidin-5-y1)-1-oxo -2-pheny1-1,2-dihydroisoquinolin-3-yl)ethyl)amino)quinazoline-6-carbonitrile [395] '1-1-NMR (400MHz, CDC13) 8 8.52(s, 1H), 8.41(s, 2H), 8.27(s, 1H), 7.88(d, 2H), 7.66(m, 1H), 7.55(m, 1H), 7.46(m, 1H), 7.30(m, 3H), 7.20(m, 1H), 7.10(m, 1H), 6.71(s, 1H), 6,37(d, 1H), 5.15(m, 1H), 3.96(s, 3H), 1.54(d, 3H); (Yield: 55%) [396]
[397] Example 34. (S)-44(1-(8-(2-ethoxypyrimidin-5-y1)-1-oxo -2-pheny1-1,2-dihydroisoquinolin-3-yl)ethyl)amino)quinazoline-6-carbonitrile [398] 1H-NMR (400MHz, CDC13) 8 8.51(s, 1H), 8.43(s, 1H), 8.40(s, 2H), 7.86(m, 2H), 7.66(m, 2H), 7.55(m, 1H), 7.33(m, 1H), 7.23(m, 1H), 7.17(m, 2H), 6.94(d, 1H), 6.70(s, 1H), 5.10(m, 1H), 4.34(m, 2H), 1.50(d, 3H), 1.25(t, 3H); (Yield: 71%) [399]
[400] Example 35. (S)-44(1-(8-(2-(dimethylamino)pyrimidin-5-y1)-1-oxo -2-phenyl-1,2-dihydroisoquinolin-3-ypethypamino)quinazoline-6-carbonitrile [401] '1-1-NMR (400MHz, CDC13) ô 8.51(s, 1H), 8.24(d, 3H), 7.85(m, 2H), 7.61(m, 1H), 7.45(m, 2H), 7.32(m, 3H), 7.21(m, 1H), 7.14(m, 1H), 6.63(s, 1H), 6.40(m, 1H), 5.04(m, 1H), 3.03(s, 6H), 1.49(d, 3H); (Yield: 54%) [402]
[403] Example 36. (S)-44(1-(8-(2-methylpyrimidin-5-y1)-1-oxo -2-pheny1-1,2-dihydroisoquinolin-3-yl)ethyl)amino)quinazoline-6-carbonitrile [404] 'H-NMR (400MHz, CDC13) 8 8.55(s, 3H), 8.34(s, 1H), 7.88(m, 2H), 7.69(m, 1H), 7.60(m, 1H), 7.57(m, 1H), 7.47(m, 2H), 7.31(m, 2H), 6.69(s, 1H), 6.56(d, 1H), 5.03(m, 1H), 2.61(s, 3H), 1.50(d, 3H); (Yield: 63%) [405]
[406] Example 37. (S)-44(1-(8-(2-cyclopropylpyrimidin-5-y1)-1-oxo -2-phenyl-1,2-dihydroisoquinolin-3-yl)ethypamino)quinazoline-6-carbonitrile [407] 'H-NMR (400MHz, CDC13) ô 8.53(s, 1H), 8.46(s, 2H), 8.32(s, 1H), 7.85(m, 2H), 7.66(m, 1H), 7.58(m, 1H), 7.47(m, 1H), 7.31(m, 3H), 7.21(m, 2H), 6.68(s, 1H), 6.57(d, 1H), 5.02(m, 1H), 2.08(m, 1H), 1.49(d, 3H), 1.00(m, 2H), 0.95(m, 2H); (Yield:
51%) [408]
[409] Example 38. (S)-44(1-(2-(4-fluoropheny1)-8-(2-methylpyrimidin-5-y1 )-1-oxo-1,2-dihydroisoquinolin-3-yl)ethyl)amino)quinazoline-6-carbonitrile [410] 'H-NMR (400MHz, CDC13) 8 8.61(s, 1H), 8.56(s, 2H), 8.43(s, 1H), 7.91(q, 2H), 7.68(t, 1H), 7.58(d, 1H), 7.47-7.43(m, 1H), 7.30-7.16(m, 3H), 6.99(t, 1H), 6.70(s, 1H), 6.62(d, 1H), 5.01(m, 1H), 2.65(s, 3H), 1.52(d, 3H); (Yield: 54%) [411]
[412] Example 39. (S)-44(1-(1-oxo-2-pheny1-8-(pyrimidin-5-y1 )-1,2-dihydroisoquinolin-3-yl)propyl)amino)quinazoline-6-carbonitrile [413] 'H-NMR (400MHz, CDC13) 8 9.07(s. 1H), 8.67(s, 2H), 8.59(s, 1H), 8.35(s, 1H), 7.91(m, 1H), 7.69(m, 1H), 7.61(m, 1H), 7.51(m, 1H), 7.39(m, 1H), 7.31-7.21(m, 4H), 6.69(s, 1H), 6.26(m, 1H), 4.94(br, 1H), 2.05-1.95(m, 1H), 1.88-1.84(m, 1H), 0.91(t, 3H); (Yield: 59%) [414]
[415] Example 40. (S)-4-((1-(8-(2-methoxypyrimidin-5-y1)-1-oxo -2-phenyl-1,2-dihydroisoquinolin-3-yl)propyl)amino)quinazoline-6-carbonitrile [416] 11-1-NMR (400MHz, CDC13) ö 8.56(s, 1H), 8.43(s, 2H), 8.29(s, 1H), 7.91(m, 2H), 7.65(m, 1H), 7.55-7.49(m, 2H), 7.37(m, 2H), 7.26-7.22(m, 2H), 7.20(d, 1H), 6.67(s, 1H), 6.10(m, 1H), 4.98(m, 1H), 3.97(s, 3H), 1.98(m, 1H), 1.86(m, 1H), 0.92(t, 3H);
(Yield: 65%) [417]
[418] Example 41. (S)-4-((1-(8-(2-ethoxypyrimidin-5-y1)-1-oxo -2-phenyl-1,2-dihydroisoquinolin-3-yppropyl)amino)quinazoline-6-carbonitrile [419] 'H-NMR (400MHz, CDC13) ô 8.57(s, 1H), 8.42(s, 2H), 8.31(s, 1H), 7.90(m, 2H), 7.65(m, 1H), 7.55(m, 2H), 7.37(m, 2H), 7.24-7.21(m, 2H), 7.20(d, 1H), 6.67(s, 1H), 6.24(d, 1H), 4.96(m, 1H), 4.13(q, 2H), 1.97(m, 1H), 1.85(m, 1H), 1.39(t, 3H), 0.92(t, 3H); (Yield: 51%) [420]
[421] Example 42. (S)-4-((1-(8-(2-methylpyrimidin-5-y1)-1-oxo -2-pheny1-1,2-dihydroisoquinolin-3-yl)propyl)amino)quinazoline-6-carbonitrile [422] 11-1-NMR (400MHz, CDC13) 8 8.85(s, 1H), 8.58(d, 3H), 8.28(s, 1H), 7.92(m, 2H), 7.67(m9 1H), 7.58(m, 1H), 7.52(m, 1H), 7.40(m, 21-1), 7.32(m, 1H), 7.23(m, 1H), 6.68(s, 1H), 6.11(m, 1H), 4.96(m, 1H), 2.69(s, 3H), 1.99(m, 1H), 1.84(m, 1H), 0.92(t, 3H); (Yield: 53%) [423]
[424] Example 43. (S)-8-(2-aminopyrimidin-5-y1)-3-(1-((5-fluoroquinazolin -4-yl)amino)ethyl)-2-phenylisoquinolin-1(2H)-one [425] 11-1-NMR (400MHz, CDC13) 8 8.46(s, 1H), 8.25(s, 2H), 7.65(m, 3H), 7.52(m, 1H), 7.45(m, 2H), 7.28-7.12(m, 5H), 6.70(s, 1H), 6.60(m, 1H), 5.08(m, 3H), 1.52(t, 3H);
(Yield: 58%) [426]
[427] Example 44. (S)-8-(2-fluoropyrimidin-5-y1)-3-(14(5-fluoroquinazolin -4-yl)amino)ethyl)-2-phenylisoquinolin-1(2H)-one [428] 'H-NMR (400MHz, CDC13) 8 8.55(s, 1H), 8.17(br, 1H), 7.65(m, 3H), 7.55(m, 1H), 7.46(m, 2H), 7.34(m, 1H), 7.28(m, 3H), 7.24(m, 1H), 7.21(m, 1H), 6.69(s, 1H), 6.66(m, 1H), 5.09(m, 1H), 1.53(d, 3H); (Yield: 50%) [429]
[430] Example 45. (S)-3-(1#5-fluoroquinazolin-4-yDamino)-2-methylpropyl )-2-phenyl-8-(pyrimidin-5-yl)isoquinolin-1(2H)-one [431] 'H-NMR (400MHz, CDC13) 8 9.09(s, 1H), 8.68(s, 2H), 8.55(s, 1H), 7.66(m, 4H), 7.61(m, 1H), 7.58(m, 2H), 7.46(m, 1H), 7.27(m, 2H), 7.21(m, 1H), 6.92(m, 1H), 6.58(s, 1H), 4.98(m, 1H), 2.06(m, 1H), 1.05(d, 3H), 0.80(d, 3H); (Yield: 61%) [432]
[433] Example 46. (S)-8-(2-aminopyrimidin-5-y1)-3-(14(5-fluoroquinazolin -4-yl)amino)-2-methylpropy1)-2-phenylisoquinolin-1(2H)-one [434] 1H-NMR (400MHz, CDC13) 8 8.55(s, 1H), 8.25(s, 2H), 7.67-7.59(m, 4H), 7.52(m, 4H), 7.49(m, 1H), 7.20(m, 2H), 6.92(m, 1H), 6.54(s, 1H), 4.98(m, 1H), 4.96(s, 2H), 2.06(m, 1H), 1.04(d, 3H), 0,80(d, 3H); (Yield: 63%) [435]
[436] Example 47. (S)-3-(1-((5-fluoroquinazolin-4-yDamino)-2-methylpropyl )-8-(2-methylpyrimidin-5-y1)-2-phenylisoquinolin-1(2H)-one [437] 4-1-NMR (400MHz, CDC13) ô 8.59(s, 2H), 8.54(s, 1H), 7.70-7.60(m, 4H), 7.56-7.42(m, 4H), 7.28(m, 1H), 7.20(m, 2H), 6.93(m, 1H), 6.57(s, 1H), 4.98(m, 1H), 2.71(s, 3H), 2.06(m, 1H), 1.03(d, 3H), 0.79(d, 3H); (Yield: 53%) [438]
[439] Experimental Example 1. Assay for phosphatidylinositol 3-kinase delta (PI3Ko) activity [440] The compounds of the present invention were tested for the activity of phos-phatidylinositol 3-kinase delta (PI3K8) by using a PI3K enzyme-homogeneous time resolved fluorescence (PI3K-HTRF) kit, which is available under UpstateTM kit (Millipore Co, Billerica, MA, USA). This kit system measures indirectly the amount of PIP3 produced via PI3K by detecting competitive inhibition of fluorescence complex formation.
[441] There were used three kinds of buffer solutions, i.e., reaction buffer, stop solution, and detection solution. The reaction buffer was prepared by diluting Reaction Buffer (provided in UpdateTM kit) with distilled water 4 times and adding DTT to a con-centration of 5 mM. The stop solution was prepared by combining STOP A and B
Solutions (provided in UpdateTm kit) in a ratio of 3:1. The detection solution was prepared by combining Detection Solution A, B and C (provided in UpdateTm kit) in a ratio of 1:1:18. A substrate solution and an ATP solution were prepared by diluting the 1mM PIP2 (phosphatidyl inositol 4,5 bi-phosphate) stock solution (provided in Update TM kit) and 10 mM ATP (Sigma-aldrich Co., St. Louis, MO, USA) stock solution with the reaction buffer to concentrations of 20 1tM and 40 tM, respectively. An enzyme solution was prepared by diluting PI3K8 (#14-604; UpstateTm kit) with the substrate solution to the concentration of 0.2lig/m1 (final reaction concentration: 0.1 ig/m1).
[442] The test groups were prepared by dissolving each compound in 100%
DMSO at 40x the final concentration and then diluting 10-fold with the reaction buffer. 5 ill of each diluted test group solution was transferred to a 384 well low flange white flat bottom microplate (#3572, Corning Life Sciences, Lowell, MA, USA). We performed centrifuge (1 minute, 1000 rpm) and shaking for 2 minutes after every solution-adding step in this experiment. Next, 10 ill of the enzyme solution was added to each well. A
mixed solution of the substrate solution (10 IA) plus 51x1 of the 100% DMSO
diluted solution without test compound (i.e., 10% DMSO solution) was used as a negative control. And also, a mixed solution of enzyme solution (10 i's) plus 5 ill of the 100%
DMSO diluted solution without test compound (i.e., 10% DMSO solution) was used as a positive control. This plate was pre-incubated for 10 minutes in a 25 C
incubator.
After the pre-incubation, the phosphorylation reaction was induced by adding 5 ill of the ATP solution and the plate was incubated for 30 minutes in a 25 C
incubator. This enzyme reaction was stopped by 5 ill of the stop solution and then 5 ill of the detection solution was added thereto. To obtain enough fluorescence responses, the plate was incubated for 2 hours in a 25 C incubator protected from light.
[443] The time-resolved fluorescence resonance energy transfer (TR-FRET) rate was measured (emission wavelength: 665 nm, 620 nm, excitation wavelength: 313 nm) by using a Flexstation3 Micro plate reader (Molecular Devices, USA). TR-FRET Rate was calculated based on the Equation 1 and using these TR-FRET Rates, %
inhibition rate of each compound was calculated based on the Equation 2. The IC50 values, i.e., the concentration of a test compound that inhibits 50% of P1310 activity in vitro, are generated by Softmax program (Molecular Devices, USA). The results are shown in Table 1 below.
[444] <Equation 1>
[4451 TR-FRET Rate = (Signal at 665 nm emission wavelength / Signal at 620 nm emission wavelength) X 10000 [446] <Equation 2>
[447] % Inhibition Rate = [(TR-FRET Rate of the test group - TR-FRET Rate of the positive control group) / (TR-FRET Rate of the negative control group - TR-FRET
Rate of the positive control group)] X 100 [448]
[449] Experimental Example 2. Assay for phosphatidylinositol 3-kinase alpha, beta and gamma (PI3Ka, PI31(13 and PI3Ky) activities [450] The compounds of the present invention were assayed for the activities of PI3K
subtypes, i.e., PI3Ka, P131(13 and PI3Ky, using the same procedures as in Experimental Example 1. PI3Ka (phosphatidylinositol 3-kinase alpha, #14-602; UpstateTM
kit), P131(13 (phosphatidylinositol 3-kinase beta, #14-603; UpstateTM kit) and PI3Ky (phosphatidylinositol 3-kinase gamma, #14-558; UpstateTm kit) were used for the test instead of PI31(8. In order to test the sensitivities of compounds to each enzyme in the same condition, the EC65values (final reaction concentrations) for each enzyme were measured. Determined EC65 values are 0.1 pg/m1 for PI3Ka, 0.4 vg/m1 for P131(13, and 0.4 pg/m1 for PI3Ky, respectively. Enzyme solution was prepared to a 2-fold the final concentration. The IC50 values were calculated by the same manners as in Ex-perimental Example 1. The results are shown in Table 1 below.
[451] <Table 1>

[452] Example In vitro enzyme assay (IC50, nM) PI3Ka PI3K13 Pl3KO PI3Ky (p110a/p85a)(h) (p11013/p85a)(h) (p1106/p85a)(h) (p120y)(h) 3416 7501 17 465 _ _ _
13 1481 10000 24 2889
14 841 10000 3 537 . .
2438 8950 15 819 _ 24 8120 10000 17 _ 4280 _ - .
33 1240 6690 10 155 _ 36 730 10000 5 86 _ _ -10000 10000 17 , >1000 -47 10000 10000 23 >1000 [453] Experimental Example 3. Evaluation of antitumor activity in a mouse colorectal cancer model [454] The anti-tumor efficacy of the compound according to the present invention was evaluated in murine syngeneic tumor model. The evaluation method includes subcu-taneously implanting CT26 cells, a murine colon carcinoma cell known to have high immunogenicity, into the right flank in mouse to induce tumor growth and an immune response thereto; and confirming an anti-tumor efficacy of the compound through the tumor growth inhibition.
[455] To establish CT26 murine syngeneic colon tumor model, 6-weeks-old BALB/c female mice (purchased from Hanlim Experimental Animal Laboratory) were prepared and acclimated for 1 week in an animal breeding facility. CT26 tumor cells (No. 80009) were obtained from Korea Cell Line Bank (KCLB, Korea) and cultured according to standard mammalian cell culture protocol. The tumor cells were diluted with a phosphate buffered saline to a concentration of 1 x 107 cells/ml. The tumor cell suspension (100 Ill/mouse) was subcutaneously implanted into the right flank in mice. To monitor tumor growth, tumor volumes were measured twice weekly in two dimensions using a digital caliper. The tumor volume was calculated using the calculation "tumor volume = 1/2 x long axis x short axis2". CT26 tumor bearing mice were randomized to several test groups based on their tumor volume and body weight. The drug was treated when the average tumor volume in the test groups was about 100 mm3. As a negative control, isotype Rat IgG was used. As a positive control, anti-PD-Li antibody (BioXcell) was used. The control antibodies were diluted in phosphate buffered saline. The compound of the present invention (Compound A, i.e., the compound of Example 25) was suspended in a solution containing 0.5% methyl cellulose and 0.2% Tween' 80 and then administered. The control antibody was intraperitoneally administered at a dose of 5 ml/kg, three times in total (i.e., at days 0, 4, and 7 from the day of initiation of administration). The compound of Example 25 (Compound A) was orally administered at a dose of 10 ml/kg twice a day (i.e., the BID administration at a.m./p.m.), every day.
[456] Tumor volume and body weight were measured twice weekly along with the progress of the administration, and the tumor volumes were measured by the method described above. The anti-tumor efficacies according to the administration of the compound alone and the combination of the compound and the anti-PD-L1 antibody are shown in FIG. 1. From the results of FIG. 1, it can be seen that the compound of the present invention not only exhibits excellent anti-tumor efficacy, but also exhibits synergistic anti-tumor efficacy when combined with an immune-checkpoint inhibitor.
Date Recue/Date Received 2023-05-18

Claims (16)

WHAT IS CLAIMED IS:
1. A compound of Formula 1 or its pharmaceutically acceptable salt:
wherein, W is N or CH, Ri is hydrogen; a C1-6 alkyl group; a C3-8 cycloalkyl group; a C1-6 alkoxy group; an amino group; a C1-6 alkylamino group; a C1-6 alkylthio group; or a halogen group, R2 is hydrogen; a C1-6 alkyl group; a C3_8 cycloalkyl group; a C3_8 heterocycloalkyl group; a substituted or unsubstituted aryl group; or a substituted or unsubstituted heteroaryl group, R3 is hydrogen; a C1-6 alkyl group; a C3-8 cycloalkyl group; or a C3-8 heterocycloalkyl group, and Cy is a group of the following Formula A or B, where * in Formulas A and B
represents the position attached to the compound of Formula 1 <BIG>
Date Recue/Date Received 2023-05-18
2. The compound or its pharmaceutically acceptable salt of claim 1, wherein R2 is a C3-8 cycloalkyl group or a phenyl group optionally substituted with halogen.
3. The compound or its pharmaceutically acceptable salt of claim 1, wherein R3 is a C1-6 alkyl group or a C3-8 cycloalkyl group.
4. The compound or its pharmaceutically acceptable salt of claim 1, wherein W is N, Ri is hydrogen; a C1-6 alkyl group; a C1-6 alkoxy group; an amino group; a C1-alkylamino group; a C1-6 alkylthio group; or a halogen group, R2 is a C3-8 cycloalkyl group or a phenyl group, and R3 is a C1-6 alkyl group or a C3_8 cycloalkyl group.
5. The compound or its pharmaceutically acceptable salt of claim 4, wherein RI
is hydrogen; a C1-6 alkyl group; a C1-6 alkoxy group; an amino group; a Ci_6 alkylthio group; or a halogen group.
6. The compound or its pharmaceutically acceptable salt of claim 5, wherein Ri is hydrogen; a Ci_6 alkyl group; a C1_6 alkoxy group; or an amino group.
7. The compound or its pharmaceutically acceptable salt of claim 6, wherein RI
is a C1-6 alkoxy group or an amino group and R2 is a phenyl group.
8. The compound or its pharmaceutically acceptable salt of claim 4, which is :
(S)-4-((1 -(4-oxo-3-pheny1-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yl)ethyl)ami no)quinazoline-6-carbonitrile;
(S)-4-(( 1 -(5-(2-aminopyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)et hyl)amino)quinazoline-6-carbonitrile;
(S)-4-(( 1 -(5-(2-methylpyri mi di n-5-y1)-4-oxo-3-ph eny1-3 ,4-di hy dro quinaz ol in-2-yl)e Date Recue/Date Received 2023-05-18 thyl)amino)quinazoline-6-carbonitri le;
(S)-4-((1 -(4-oxo-3-pheny1-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yl)propyl)am ino)quinazoline-6-carbonitrile;
(S)-4-(( 1 -(5-(2-methoxypy rim i din-5-y1)-4-oxo-3 -pheny1-3,4-dihy droquinazolin-2-y1 )propyl)amino)quinazoline-6-carbonitril e;
(S)-4-((1 -(5-(2-ethoxypyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)p ropyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1 -(5-(2-(dim ethyl ami no)pyrim din-5-y1)-4-oxo-3 -ph eny1-3 ,4 -di hydroquin azo lin-2-yl)propyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1 -(5-(2-(methylsulfanyl)pyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazo lin-2-yl)propyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1 -(5-(2-methylpyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)b utyl)amino)quinazoline-6-carboni tri le;
(S)-4-(( 1 -(5-(2-methoxypy rim idin-5-y1)-4-oxo-3 -pheny1-3,4-dihy droquinazolin-2-y1 )butyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1 -(5-(2-ethoxypyrimi din -5-y1)-4-ox o-3-ph eny1-3 ,4-dihydroquinazolin-2-yl)b utyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1 -(5-(2-aminopyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-yl)b utyl)amino)quinazoline-6-carbonitri le;
(S)-4-((1 -(5-(2-aminopyrimidin-5-y1)-4-oxo-3-pheny1-3,4-dihydroquinazolin-2-y1)-2 -methylpropyl)amino)quinazoline-6-carbonitrile;
(S)-4-((cy clopropy1(4-oxo-3 -pheny1-5-(pyrimi din-5 -y1)-3,4-dihy droquinaz olin-2-y1) methyl)amino)quinazoline-6-carbonitri le;
(S)-4-((cy clopropy1(5-(2-methoxypyrimi din-5-y1)-4-oxo-3-ph eny1-3,4-di hy droquina zolin-2-yl)methyl)amino)quinazoline-6-carbonitrile;
(S)-4-((cy clopropyl (5-(2-ethoxypy rimi di n-5-y1)-4-oxo-3 -pheny1-3 ,4 -di hydroquinazo lin-2-yl)methyl)amino)quinazoline-6-carbonitri le;
(S)-4-((1 -(3-cyclopropy1-4-oxo-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yl)ethyl )am ino)quinazoline-6-carbonitrile;
Date Recue/Date Received 2023-05-18 (S)-4-((1 -(3-cy clopropy1-5-(2-m ethoxypyrimi din-5 -y1)-4-oxo-3,4 -di hy dro qui naz olin -2-yl)ethyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1-(3-cyclopropy1-5-(2-ethoxypyrimidin-5-y1)-4-oxo-3,4-dihydroquinazolin-2 -ypethypamino)quinazoline-6-carbonitrile;
(S)-4-((1-(3-cyclopropy1-4-oxo-5-(pyrimidin-5-y1)-3,4-dihydroquinazolin-2-yl)prop yl)amino)quinazoline-6-carbonitrile;
(S)-4-((1-(5-(2-aminopyrimidin-5-y1)-3-cyclopropy1-4-oxo-3,4-dihydroquinazolin-yl)propyl)amino)quinazoline-6-carbonitrile;
(S)-2-(145-fluoroquinazolin-4-yDamino)ethyl)-3-phenyl-5-(pyrimidin-5-yl)quinazo lin-4(3H)-one;
(S)-5-(2-am inopy rimi din-5 -y1)-2-(1-((5 -fluoroquinazolin-4-yl)amino)ethyl)-3-pheny lquinazolin-4(311)-one;
(S)-2-(1 -((5 -fluoroquinazolin-4-yl)ami no)propy1)-3 -pheny1-5-(pyrimi din-5-yl)quina zolin-4(3H)-one;
(S)-5-(2-aminopyrimidin-5-y1)-2-(145-fluoroquinazolin-4-yl)amino)propy1)-3-phen ylquinazolin-4(31f)-one;
(S)-5-(2-fluoropyrimi din-5 -y1)-2-(1 -((5 -fluoroquinazolin-4-yl)amino)propy1)-3-phen ylquinazolin-4(3H)-one;
(S)-2-(145-fluoroquinazolin-4-yl)amino)propy1)-5-(2-methylpyrimidin-5-y1)-3-phe nylquinazolin-4(3H)-one;
(S)-2-(1-((5-fluoroquinazolin-4-yl)amino)-2-methylpropy1)-3-pheny1-5-(pyrimidin-5 -yl)quinazolin-4(3H)-one;
(S)-5-(2-aminopyrimidin-5-y1)-2-(145-fluoroquinazolin-4-y0amino)-2-methylprop y1)-3-phenylquinazolin-4(3H)-one;
(S)-2-(cyclopropyl((5-fluoroquinazolin-4-yl)amino)methyl)-3-phenyl-5-(pyrimidin-5-yl)quinazolin-4(3H)-one; or (S)-5-(2-aminopyrimidin-5-y1)-2-(cyclopropy1((5-fluoroquinazolin-4-yl)amino)meth y1)-3-phenylquinazolin-4(3H)-one.
Date Recue/Date Received 2023-05-18
9. The compound or its pharmaceutically acceptable salt of claim 1, wherein W is CH;
Ri is hydrogen; a C1-6 alkyl group; a C3-8 cycloalkyl group; a C1-6 alkoxy group; an amino group; a C1_6 alkylamino group; or a halogen group, R2 is a phenyl group optionally substituted with halogen, and R3 is a C1_6 alkyl group.
10. The compound or its pharmaceutically acceptable salt of claim 9, wherein Ri is hydrogen; or a C1-6 alkyl group; a C1-6 alkoxy group; an amino group; or a halogen group, and R2 is a phenyl group.
11. The compound or its pharmaceutically acceptable salt of claim 10, wherein RI is a C1-6 alkyl group or a C1-6 alkoxy group.
12. The compound or its pharmaceutically acceptable salt of claim 9, which is:
(S)-4-((1-(1-oxo-2-pheny1-8-(pyrimidin-5-y1)-1,2-dihydroisoquinolin-3-ypethyl)ami no)quinazoline-6-carbonitrile;
(S)-4-((1-(8-(2-methoxypyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-y1 )ethyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1-(8-(2-ethoxypyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-yl)e thyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1-(8-(2-(dimethylamino)pyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquin olin-3-ypethypamino)quinazoline-6-carbonitrile;
(S)-4-((1-(8-(2-methylpyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroisoquinolin-3-y1) ethyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1-(8-(2-cyclopropylpyrimidin-5-y1)-1-oxo-2-pheny1-1,2-dihydroi soquinolin-3-yl)ethyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1-(2-(4-fluoropheny1)-8-(2-methylpyrimidin-5-y1)-1-oxo-1,2-dihydroisoquin olin-3-yl)ethyl)amino)quinazoline-6-carbonitrile;
Date Recue/Date Received 2023-05-18 (S)-4-((1-(1-oxo-2-pheny1-8-(pyrimidin-5-y1)-1,2-dihydroisoquinolin-3-yl)propyl)a mino)quinazoline-6-carbonitrile;
(S)-4-((1 -(8-(2-m eth oxypyrim i din -5-y1)-1 -ox o-2-ph eny1-1,2-dihy droi s oquinolin -3-y1 )propy Damino)quinazoline-6-c arb oni trile;
(S)-4-((1-(8-(2-ethoxypyrimi di n-5-y1)-1 -ox o-2-ph eny1-1,2-dihydroi s oquinolin-3 -y1) propyl)amino)quinazoline-6-carbonitrile;
(S)-4-((1-(8-(2-methylpyrimi din-5-y1)-1-oxo-2-pheny1-1,2-dihydroi s oquinolin-3-y1) propyl)amino)quinazoline-6-carbonitrile;
(S)-8-(2-aminopyrimidin-5 -y1)-3 -(145 -fluoroqui nazolin-4-yl)ami no)ethyl)-2-pheny lisoquinolin-1(211)-one;
(S)-8-(2-fluoropyrimi di n-5 -y1)-3 -(1 -((5 -fluoroquinazolin-4-yl)amino)ethyl)-2-pheny lisoquinolin-1(2H)-one;
(S)-3-(1 -((5 -fluoroquinazolin-4-yl)ami no)-2-methylpropy1)-2-phenyl -8-(pyrimi din-5 -yl)isoquinolin-1(2H)-one;
(S)-8-(2-aminopyrimi din-5-y1)-3 -(1 -((5 -fluoroquinazolin -4-yl)amino)-2-methylprop y1)-2-phenylisoquinolin-1(211)-one; or (S)-3-(1 -((5 -fluoroquinazolin-4-yl)ami no)-2-methylprop y1)-8-(2-methy 1pyrim i di n-5-y1)-2-phenyl i s oqui nob n-1(211)-on e .
13. A pharmaceutical composition comprising a compound of Formula 1 or its pharmaceutically acceptable salt as defined in any one of claims 1 to 12 and a pharmaceutically acceptable canier.
14. The pharmaceutical composition of claim 13, further comprising an immune-checkpoint inhibitor.
15. Use of a therapeutically effective amount of a compound of Formula 1 or its pharmaceutically acceptable salt as defined in any one of claims 1 to 12, or a pharmaceutical composition as defined in claim 13 or 14, for selectively inhibiting phosphatidylinositol Date Recue/Date Received 2023-05-18 3-kinase delta subunit in a mammal.
16. A
compound of Formula 1 or its pharmaceutically acceptable salt as defined in any one of claims 1 to 12, or a pharmaceutical composition as defined in claim 13 or 14, for use in selectively inhibiting phosphatidylinositol 3-kinase delta subunit in a mammal.
Date Recue/Date Received 2023-05-18
CA3019333A 2016-04-29 2017-04-26 Quinazoline derivative or its salt and pharmaceutical composition comprising the same Active CA3019333C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0053033 2016-04-29
KR20160053033 2016-04-29
PCT/KR2017/004424 WO2017188720A2 (en) 2016-04-29 2017-04-26 Quinazoline derivative or its salt and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
CA3019333A1 CA3019333A1 (en) 2017-11-02
CA3019333C true CA3019333C (en) 2024-01-02

Family

ID=60159881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3019333A Active CA3019333C (en) 2016-04-29 2017-04-26 Quinazoline derivative or its salt and pharmaceutical composition comprising the same

Country Status (9)

Country Link
US (1) US10941136B2 (en)
EP (1) EP3448839B1 (en)
JP (1) JP6909236B2 (en)
KR (1) KR102325899B1 (en)
CN (1) CN109071462B (en)
AU (1) AU2017256488B2 (en)
CA (1) CA3019333C (en)
ES (1) ES2908001T3 (en)
WO (1) WO2017188720A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3019333C (en) * 2016-04-29 2024-01-02 Yuhan Corporation Quinazoline derivative or its salt and pharmaceutical composition comprising the same
US20200165257A1 (en) * 2017-06-22 2020-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer
WO2019143874A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CN113929674B (en) * 2021-11-22 2023-09-22 中国药科大学 Compounds containing 1,4-dihydroquinazoline structure and preparation methods and applications thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2775942A1 (en) 2009-09-29 2011-04-07 Xcovery Holding Company Llc Pi3k (delta) selective inhibitors
BR112012019635A2 (en) * 2010-02-22 2016-05-03 Hoffmann La Roche pyrido [3,2-d] pyrimidine pi3k delta inhibitor compounds and methods of use
EP2734520B1 (en) * 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013285081B2 (en) 2012-07-04 2017-01-12 Rhizen Pharmaceuticals Sa Selective PI3K delta inhibitors
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CA3019333C (en) * 2016-04-29 2024-01-02 Yuhan Corporation Quinazoline derivative or its salt and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
EP3448839B1 (en) 2022-02-09
AU2017256488A1 (en) 2018-09-20
US20200325120A1 (en) 2020-10-15
US10941136B2 (en) 2021-03-09
JP2019514910A (en) 2019-06-06
AU2017256488B2 (en) 2020-12-17
KR102325899B1 (en) 2021-11-12
CN109071462A (en) 2018-12-21
EP3448839A4 (en) 2019-09-11
ES2908001T3 (en) 2022-04-27
JP6909236B2 (en) 2021-07-28
WO2017188720A3 (en) 2018-07-26
WO2017188720A2 (en) 2017-11-02
CN109071462B (en) 2022-02-08
EP3448839A2 (en) 2019-03-06
CA3019333A1 (en) 2017-11-02
KR20170124089A (en) 2017-11-09

Similar Documents

Publication Publication Date Title
CA3019333C (en) Quinazoline derivative or its salt and pharmaceutical composition comprising the same
US9550738B2 (en) Bicyclic compounds as kinases inhibitors
CN111909181B (en) A class of ubiquitination specific protease inhibitors and its preparation method and application
US20200299295A1 (en) Inhibiting creb binding protein (cbp)
US12338251B2 (en) Substituted macrocycles useful as kinase inhibitors
JP6916562B2 (en) Compounds, pharmaceutically acceptable salts thereof, solvates, stereoisomers and tautomers, and drug compositions, hyperproliferative disorder therapeutic agents, hyperproliferative disorder prophylaxis agents, drugs, cancer therapeutic agents, cancer Prophylactic agents and kinase signaling regulators
JP6609308B2 (en) Substitutional macrocycles as kinase inhibitors
WO2016026423A1 (en) Substituted macrocycles useful as kinases inhibitors and methods of use thereof
CN115160309B (en) KRAS G12C Preparation and application of mutant protein heterocyclic inhibitor
WO2015117547A1 (en) Substituted pyrimidines useful as egfr-t790m kinase inhibitors
WO2020038433A1 (en) Egfr kinase inhibitor, preparation method therefor, and application thereof
AU2015303724B2 (en) Quinazoline derivative
JP2025516292A (en) Compound containing 2,4-diaminopyrimidine, its production method, and pharmaceutical composition for preventing or treating cancer containing the same as an active ingredient
CN113880845A (en) Pyrrolotriazine derivatives, and preparation method and application thereof
CN115772156B (en) Compound used as HPK1 kinase inhibitor and preparation method and application thereof
US12391666B2 (en) Indoline-1-formamide compound, preparation method therefor, and medical use thereof
WO2023010354A1 (en) Small molecule compound having egfr inhibitory activity, and preparation method therefor and use thereof
TW202315866A (en) Quinazoline compound, composition, and application thereof
KR20240156074A (en) HPK1 and MLK3 inhibitor and anticancer compositions containing the same
UA76103C2 (en) Inhibitors of phosphatidyl-inositol- 3-kinase delta of human

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220207

EEER Examination request

Effective date: 20220207

EEER Examination request

Effective date: 20220207

EEER Examination request

Effective date: 20220207

EEER Examination request

Effective date: 20220207

EEER Examination request

Effective date: 20220207

EEER Examination request

Effective date: 20220207